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 Calcific Aortic Valve Disease (CAVD), characterized by aortic valve (AV) stenosis 
and insufficiency (regurgitation), is a major cause of cardiac-related deaths worldwide, 
especially in the aging population in advanced countries [6-8]. Once developed, it is treated 
mainly with AV repair or replacement by surgical or transcathether methods [9, 10]; 
however, there are currently no pharmacological treatment options for these patients. This 
is largely due to a relative paucity in molecular mechanistic understanding of the disease. 
CAVD was once thought to be a passive degenerative disease, but overwhelming evidence 
demonstrates that it is actively regulated by cellular and molecular pathways that lead to 
AV inflammation, sclerosis (thickening and fibrosis), and calcific lesions  [11-13].  
MicroRNAs (miRNAs) are a large class of evolutionarily conserved, noncoding RNAs 
which function as post-transcriptional regulators by interacting with the 3’ untranslated 
region (3’UTR) of specific target mRNAs in a sequence-specific manner. A single miRNA 
can typically target hundreds of mRNAs. These miRNAs negatively regulate gene 
expression through translational repression or mRNA cleavage, depending on the degree 
of complementarity. Flow-sensitive miRNAs have been mostly characterized in vitro 
however, their role in human disease has not been fully studied. 
Previous work in our laboratory has focused on identifying shear-sensitive and side-
specific (ventricularis compared to fibrosa layers of the AV) miRNAs relevant to CAVD. 
To this end, we conducted two independent microRNA array studies. First, we isolated 
human aortic valve endothelial cells (HAVECs) from each side of the leaflet and exposed 
them to high-magnitude unidirectional laminar shear stress (LS) or low-magnitude 
oscillatory shear stress (OS) conditions for 24 hours to discover shear-sensitive miRNAs 
[14]. Second, we isolated endothelial-enriched total RNAs from each side of the leaflet 
from porcine AVs to discover side-specific miRNAs [15]. These studies allowed us to 
identify miR-181b and miR-483 as potential miRNAs for further studies. 
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In Aim 1, we focused on studying shear-sensitive miR-181b. We showed that miR-
181b was upregulated in OS conditions and that it regulates matrix metalloproteinases 
(MMP) activity in valvular endothelium. We conducted an in silico analysis combining 
predicted gene targets of miR-181b and shear-sensitive target genes from our in vitro 
HAVEC array and identified tissue inhibitor of metalloproteinases 3 (TIMP3) as a shear-
sensitive target of miR-181b responsible for the role of miR-181b in extracellular matrix 
(ECM) degradation. Therefore, we showed that ECM degradation, a critical step in CAVD, 
might be mediated by the miR-181b/TIMP3 pathway. 
In Aim 2, we focused on studying the novel shear-sensitive miR-483-3p. We 
discovered that it regulated inflammation and endothelial-to-mesenchymal transition 
(EndMT) in HAVECs. In HAVECs we identified UBE2C as a novel shear-sensitive gene 
targeted by miR-483; which regulates endothelial inflammation and EndMT. Additionally, 
UBE2C exerts its function by silencing pVHL, which allows the upregulation and 
stabilization of HIF1α. Therapeutic studies were conducted in porcine AVs, and we showed 
that the miR-483 mimic as well as PX478, a HIF1α inhibitor, can inhibit AV calcification. 
These studies identified two potential therapeutic targets for CAVD and identified a novel 
mechanistic pathway for CAVD involving the miR-483/UBE2C/pVHL/HIF1α pathway. 
 In Aim 3, we are developing a novel accelerated in vivo model for CAVD by 
combining hypercholesterolemia (via AAV-PCSK9) and mice with bicuspid AV 
phenotype (via GATA5 knockout mice). This animal model appears to generate severe 
sclerosis and microcalcifications in AVs in just four months after PCSK9 injection, 





 Calcific aortic calve disease (CAVD), is a highly prevalent disease among the adult 
population and is associated with significant mortality and morbidity; once it is fully 
developed, the only available treatment is aortic valve (AV) repair or replacement by 
surgical or transcatheter methods [6-8]. Due in part to limited knowledge on the molecular 
pathways of CAVD, there are no pharmacological treatments available for CAVD. 
Originally CAVD was thought to be a passive degenerative disease; however, recent 
studies have demonstrated that CAVD is an actively-regulated disease characterized by 
AV inflammation, sclerosis (thickening and fibrosis), and calcific lesions [11-13].  
MicroRNAs (miRNAs) are conserved, noncoding RNAs that regulate mRNAs at the 
post-transcriptional level by interacting with the 3’ untranslated region (3’UTR) in a 
sequence-specific manner. Potential targets of miRNAs can be identified computationally, 
and most miRNAs can target hundreds of mRNAs. Once the miRNA is bound to the 3’UTR 
of the mRNA, it negatively regulates mRNA expression either by translational repression 
or by mRNA cleavage (depending on the degree of complementarity). Several flow-
sensitive miRNAs have been characterized in vitro; however, more research needs to be 
conducted to better understand the role of shear stress in miRNA function in the valvular 
endothelium. 
Previous work in our laboratory has identified shear-sensitive and side-specific 
miRNAs relevant to CAVD. Two independent miRNA array studies were conducted. First, 
in order to discover shear-sensitive miRNAs human aortic valve endothelial cells 
(HAVECs) from each side of the leaflet were isolated and exposed to high magnitude-
unidirectional shear stress (LS) or low magnitude-oscillatory shear stress (OS) conditions 
for 24 hours. Second, endothelial-enriched total RNAs from each side of the leaflet from 
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porcine AVs were isolated to discover side-specific miRNAs. From these studies. we have 
been able to identify miR-181b and miR-483 as potential miRNAs for further studies. 
In Aim 1, we studied the role of shear-sensitive miR-181b in valvular endothelial 
biology. miR-181b was upregulated in OS conditions, and it regulated matrix 
metalloproteinases (MMP) activity in AV endothelium. After identifying TIMP3 in an in 
silico analysis, we validated that TIMP3 is regulated by miR-181b in a shear-dependent 
manner. Additionally, we discovered that miR-181b regulated MMP activity by silencing 
TIMP3. Anti-miR-181b also prevented OS-induced MMP activity upregulation in 
HAVECs and can be used as a potential therapeutic to decrease ECM degradation. 
In Aim 2, we centered our attention on studying the role of the novel shear-sensitive 
miR-483-3p (miR-483). We found that in both HAVECs and the ventricularis of porcine 
AVs, miR-483 is upregulated in stable flow conditions. In HAVECs, UBE2C was 
identified as a novel shear-sensitive target regulated in a miR-483 dependent manner. miR-
483 regulated inflammation and EndMT in HAVECs by silencing UBE2C. Furthermore, 
UBE2C silenced pVHL, which lead to upregulation and stabilization of HIF1α. We 
conducted therapeutic studies in porcine AVs and showed that the miR-483 mimic, as well 
as PX478, a HIF1α inhibitor, can inhibit AV calcification. In this aim, we identified two 
potential therapeutic targets for CAVD and identified a novel pathway for CAVD 
involving the miR-483/UBE2C/pVHL/HIF1α pathway. 
 Lastly, in Aim 3 we established a new accelerated animal for CAVD by combining 
hypercholesterolemia (via AAV-PCSK9) and mice with bicuspid AV phenotype (via 
GATA5 knockout mice). This model induces severe sclerotic and calcific lesions in the 
AV in four months after PCSK9 injection, allowing for accelerated testing of CAVD 





 Aortic valve anatomy structure  
The aortic valve is a complex, heterogeneous tissue with three layers that define its 
function and behavior. The aortic valve is normally composed of three leaflets (Fig. 1.1); 
in humans, the leaflets have a thickness between 0.6 and one millimeter and are composed 
of three separate, interacting layers (as shown in Fig. 1.1): 
1. Fibrosa: This layer faces the aortic side of the valve and is comprised of valvular 
endothelial cells (VECs, in direct contact with the blood), valvular interstitial cells 
(VICs, residing below the endothelial cells), a small amount of elastin fibers, and 
circumferential type I and type III fibrillar collagen, which serves as the load-bearing 
layer. The collagen fibers are aligned along the circumference of the valve 
(circumferential) to allow for high strain under low loads and for a higher elastic 
modulus when more load is applied during the cardiac cycle[16]. In porcine aortic 
valves, the tissue is six times stiffer in the circumferential direction than the radial 
direction (along the radius of the circumference) [17, 18]; the aortic valve stretches 
considerably in the radial direction to ensure good coaptation and to avoid 
regurgitation during the diastolic phase. In diseased AVs, calcification normally 
occurs in the fibrosa (Fig. 1.1C). 
2. Spongiosa: This layer is placed between fibrosa and ventricularis and is comprised of 
VICs, a small amount of elastin fibers, glycosaminoglycans, and proteoglycans. These 
last two components serve as lubricant for the fibrosa and ventricularis layers when 
they deform during the cardiac cycle. The main component of the extracellular matrix 
in this layer is hyaluronan, which binds large amounts of water to form a foam-like 
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structure. During compression of the aortic valve, this layer absorbs energy and helps 
arrange elastin fibers on the ventricularis and collagen fibers on the fibrosa [18, 19]. 
3. Ventricularis: This layer faces the ventricular side of the aortic valve and is comprised 
of valvular endothelial cells (VECs), VICs, collagen, and radially oriented elastin 
fibers [18, 20, 21]. Collagen fibers are stretched during the diastolic phase and relaxed 
during the systolic phase as the valve compresses. Elastin fibers in this layer aid in fast 
compression during the opening phase to ensure the valve opens and closes in a fast 
and consistent manner [19]. 
The unique structure of the valve (Fig. 1.1) allows for consistent, long-term 
physiological movement due to the presence of elastin fibers throughout the tissue 
structure. The amount of collagen and elastin in the valve is 55% and 13% (dry weight), 
respectively [22]. Although collagen fibrils are stiff and have a maximum strain of 2% 
before yielding [23], they possess a crimped and wavy configuration that allows for strain 
of up to 40% without yielding [17]. Elastin serves as a scaffold between the different layers 
and helps intertwine collagen fibers between the spongiosa and fibrosa; a “honeycomb” 
arrangement of elastin surrounds collagen fibers and links them within the tissue [24]. 
Without this interconnection, the aortic valve would be at risk of delamination and 
separation of its different layers, as a consequence of the dynamic mechanical environment 




 Aortic valve disease  
A normally-functioning AV ensures the unidirectionality of blood flow from the 
left ventricle to the aorta. Abnormalities of the valve arise due to a variety of risk factors 
Figure 1.1 Aortic valve anatomy and structure.  
A) The aortic valve is located between the left ventricle (LV) and the aorta, and it regulates 
systemic blood delivery from the heart. The coaptation area (CoA) denotes the joining of 
the three leaflets to result in a tight seal. B) Valve leaflet nomenclature. The right coronary 
cusp (RCC) is the leaflet nearest to the right main coronary artery (RCA). The left coronary 
cusp (LCC) is proximal to the left main coronary artery (LCA). The noncoronary cusp 
(NCC) is the third leaflet, adjacent to the right (RA) and left atria (LA). C) Calcified 
nodules (white arrows) deposited on the fibrosa of the aortic valve (image borrowed from 
[1]). This widespread calcification is usually not observed until later stages of CAVD. D) 
Layers of the aortic valve. The fibrosa layer faces the aorta and contains less elastin and 
more collagen fibers. Interstitial cells are dispersed throughout the layers of the valve 
excluding the endothelium. The middle layer, the spongiosa, contains most of the 
interstitial cells, as well as glycosaminoglycans (GAGs) and a small amount of elastin. 
That elastin spans the spongiosa and the ventricularis, which is the side of the valve facing 
the left ventricle of the heart. The ventricularis contains a greater amount of elastin than 
the other layers and a small amount of collagen. 
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such as hypertension, high low-density lipoprotein (LDL) content, old age, 
hyperphosphatemia, diabetes, obesity, smoking, and others [26]. These valve abnormalities 
range from mild thickening to severe calcification that causes impaired leaflet motion (Fig. 
1.2). AV stenosis is a major disease characterized by the narrowing of the AV opening 
during systole, which leads to a greater pressure gradient across the valve and increased 
transvalvular velocity [27]. The classic symptoms of the AS are syncope, angina, and 
congestive heart failure. AV stenosis is a progressive disease found in the aging population; 
however, it is found in earlier ages in patients with bicuspid AV (BAV), a congenital 
condition occurring in 1-2% of all live births [28]. BAV presents elevated levels of 
turbulence downstream of the stenosed valve which causes mechanical damage to the 
endothelial layer of ascending aorta and leads to aortic aneurisms [29].  
Aortic regurgitation (AR) is a condition characterized by the AV not fully closing 
in diastole, causing a backflow of the blood from the aorta into the left ventricle. Around 
50% of the cases of AR are due to dilatation of the aortic root, which is idiopathic in most 
instances. In about 15% of regurgitation cases, the cause is innate BAV; another 15% of 
the cases are due to retraction of the cusps as part of the post-inflammatory processes of 
endocarditis in rheumatic fever and various collagen vascular diseases [30].  
Calcific AV disease is a strong risk factor for cardiovascular related deaths [12, 31, 
32] and is a significant source of mortality worldwide, with the number of patients 
requiring AV surgery expected to triple from 250,000 to 850,000 by 2050 [33]. The most 
common forms of the AV disease can be distinguished clinically by their characteristic 
echocardiographic findings. Currently, the treatment for AV calcification is to surgically 
replace the diseased valve with a mechanical or biological valve or repair.  Recent 
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developments are aimed towards the use of transcatheter AV replacement of the diseased 
valve, especially in elderly patients who do not qualify for a surgery. However, as of now, 
no proven medical therapies exist for the treatment of calcified AV leaflets.  
 
Figure 1.2 Healthy and diseased aortic valve 
On the left panel (A) a healthy tricuspid valve is shown while on the right panel (B) a 
calcified tricuspid valve is observed (adapted from deptmed.queensu.ca). 
  
 Aortic valve hemodynamics 
 As discussed previously, the aortic valve is in constant motion, resulting in an ever-
changing mechanical environment. Understanding of the dynamic mechanics of the valve 
is crucial for the study of the biological pathways that regulate CAVD. Four  types of 
forces, summarized in Figure 1.3,  are exerted upon the aortic valve: 
1. Pressure: The two faces of the valve are subjected to contrasting pressures as the 
valve opens and closes, which affect the tissue shape and geometry [34]. During 
diastole, pressure in the ventricle rapidly drops while pressure in the aorta remains 
stable. Under physiological conditions this transvalvular pressure, defined as the 
difference between the aortic and left ventricular pressure during diastole, ranges 
between 80 and 120 mmHg. In hypertensive patients, the systemic blood pressure 
is increased, and the transvalvular pressure can reach values greater than 180 
mmHg [35]. The second manifestations of arterial disease study (SMART) found 
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that systolic blood pressure has a 9% correlation with total cardiovascular 
calcifications (including aortic valve calcification) indicating that systemic 
changes in the cardiovascular system can affect the aortic valve [36]. Another 
study conducted on elderly patients found that increased ambulatory diastolic 
blood pressure was the most significant independent factor contributing to 
advanced aortic valve calcification [37]; this increase in pressure enhances the 
effect of low shear stress and cyclic stretch, accelerating the progression of aortic 
valve calcification. These two studies and others [38-40] reflect the importance of 
systemic pressure to the onset and progression of aortic valve calcification. In the 
future, specific animal studies, using models described later in this chapter, should 
be performed to better understand the effect of increased pressure on the molecular 
mechanisms of CAVD.  
2. Bending stress: Bending stress is defined as the stress generated on a solid when it 
is deformed. In the valve, bending stress causes the concave fibrosa layer to be 
compressed while the convex ventricularis layer is under tension [41]. The most 
precise model of bending stress is by Corden et al [42], who tested trileaflet 
polyurethane valves (used in ventricular assist devices and artificial hearts) under 
pulsatile flow. With this system, the group found that the bending stress for the 
polymeric valves ranges between 0.4 and 0.7 MPa, with a bending strain ranging 
from 4.7 to 8.5% at peak systole compared to the diastolic position.  
In the search for clearer models of aortic valve function, the examination of the 
bicuspid aortic valve has been invaluable. BAV is the most common congenital 
heart defect; it has a prevalence of 0.5% to 2% and a male predominance of 3 to 
1 [43]. BAV patients develop symptomatic aortic stenosis at the age of 50-60 
years old [44] while patients with tricuspid valves normally develop symptomatic 
AS at the age of 70-80 years old [45, 46]. Because patients with BAV develop 
faster and more severe AV stenosis, this condition is useful in studying aortic 
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valve calcification  and can be used to develop an accelerated in vivo model of 
CAVD.  Katayama et al [47] studied the bending strain, defined as deformation 
of the tissue caused by bending stress, in stenotic and non-stenotic tricuspid and 
bicuspid aortic valves using a computational model and concluded two findings: 
bending strain increased in stenotic tricuspid and bicuspid valves compared to 
nonstenotic valves, and a greater increase was observed in bicuspid valves, with 
strain concentrations at the midline of the leaflets. The group hypothesized that 
excessive bending strain on the bicuspid leaflets could be responsible for the rapid 
progression of calcification in bicuspid versus tricuspid valves. Another study by 
Conti et al [48] found that bicuspid aortic valves experience an eight-fold increase 
in strain compared to tricuspid valves.  Thus bending stress is clearly a critical 
factor in the valve environment, and it may be important to control the bending 
stress to prevent valve dysfunction. 
3. Axial stress: Valves change their shape and length throughout the cardiac cycle to 
adapt to the mechanical environment. Axial stress, defined as tension that the valve 
experiences perpendicular to the valve face, is paramount in creating a tight seal 
to prevent regurgitation of blood into the ventricle [41]. Axial stress is separated 
into two categories in the valve: circumferential and radial (Fig. 1.3A). In the 
aortic valve of many different species—ovine, porcine and human—the 
circumferential direction presents a higher elastic modulus than the radial 
direction [49]. In canine aortic valves, leaflets elongate from diastole to systole by 
11% in the circumferential direction and by 31% in the radial direction [50]. This 
behavior is expected because the leaflets need to stretch in the radial direction to 
form a tight seal and prevent regurgitation. Maximum axial stress in the aging 
valve is at the area where the valve leaflet attaches to the aortic root; this region is 
also where calcification is first observed [51]. This increase in stress is associated 
with development and progression of valve calcification. Furthermore, disease 
10 
 
progression leads to increased axial stress, generating a “vicious cycle” that 
accelerates valve dysfunction. 
4. Shear stress:  Shear stress is exerted on the valve by blood flowing across the face 
of the valve tissue. In basic terms, shear stress is defined as the component of the 
stress parallel to the surface of interest. Each side of the leaflet in the the aortic 
valve experiences completely different shear profiles correlating with the 
preferential calcification of the fibrosa [52, 53]. Due to the blood flow during the 
typical cardiac cycle, shear stress at the leaflet surface is experienced in a cyclical 
manner. As blood is ejected from the ventricle to the aorta, the ventricularis is 
subjected to unidirectional shear stress while the fibrosa experiences oscillatory 
shear stress. Oscillatory shear stress at the fibrosa has been directly associated with 
valve dysfunction and CAVD [52-54]. Interestingly, these disturbed conditions in 
the fibrosa side were firstly described by Leonardo da Vinci where he built a 
replica of the aortic valve and using some grass seeds he was able to demonstrate 
that the disturbed flow conditions observed in the fibrosa helped to close the valve 
to prevent backflow [55]. His work was validated in 1968 by Bellhouse et al [56]. 
Aboelkassem et al [57] derived a mathematical model combining aortic valve 
dynamics, systemic vascular resistance and sinus vortex local pressure to describe 
shear stress during systole. The model uses a Hill’s classical semi-spherical vortex 
model and an aortic pressure–area compliance constitutive relationship to 
effectively mimic the oscillatory flow experienced at the fibrosa, with a change in 
flow direction between the opening and closing sequence of the valve. This model 
nicely shows the flow forces on the valve during systole as well as the relationship 
between the blood flow and the deformation of the valve during the cardiac cycle. 
In agreement with the mathematical model, the peak shear stresses have been 
measured by another group using laser Doppler velocimetry: 20 dyn/cm2 on the 
aortic side and 64-71 dyn/cm2 on the ventricular side [58]. The results from this 
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study corroborate the theory that the fibrosa layer preferentially calcifies due to 
the low and oscillatory shear stress. Likewise, atherosclerosis presents similar 
mechanisms of disease onset such as endothelial dysfunction and inflammation 
[59] and also shows preferential development in regions of low and oscillatory 
flow [60, 61]. 
 Because endothelial cells are in direct contact with blood flow, shear stress 
is a key regulator of endothelial cell function, and can communicate systemic 
changes in the body to the valvular tissue. Laminar shear stress, as observed at the 
ventricularis, regulates cell shape and microfilament structure as cells align in the 
direction of flow [62], correlating with synthesis of endothelial nitric oxide 
synthase and production of nitric oxide, a potent vasodilator. Further discussion of 
the biological pathways altered by differential shear stresses is discussed later in 
the chapter.  
 A study conducted by Saikrishnan et al [63] utilizing bicuspid aortic valves 
constructed from porcine tricuspid valves showed reduced wall shear stress and 
increased turbulence in bicuspid valves. The study concluded that these 
differences in hemodynamics may play a key role in amplifying the biological 
responses of the valvular leaflets, which may be one of the key components in the 
accelerated progression of calcification in bicuspid aortic valves. Another valve 
computational model examined bicuspid aortic valves in a fluid-structure 
computational model, and showed that the fused leaflets of the bicuspid valve 
exhibited strong abnormalities in shear stress compared to the tricuspid controls 
[64]. The same group studied these abnormalities in ex vivo porcine aortic valve 
leaflets and found that abnormal shear stress increased endothelial inflammation 
[65]. These functional studies emphasize the importance of endothelial shear stress 
in tissue function.  
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 Mechanosensors in the aortic valve endothelium   
 Endothelial cells utilize a variety of sensing mechanisms to respond to the 
extracellular mechanical environment. Numerous studies have been carried out to further 
understand mechanosensors in the vascular endothelium [66]. However, a relatively small 
body of work has focused on the mechanical sensing of the valvular endothelial cells.  In 
the following subsections, we describe the current state of research into valvular 
endothelial mechanosensing and the major players at the cell surface, including integrins, 
GPCR, and the glycocalyx are described (Fig. 1.4).   
Figure 1.3 Forces affecting the aortic valve in systole and diastole. 
A) A cross-section of the aortic valve is shown indicating the circumferential (red dashed 
arrows) and radial direction (blue solid arrows) of the valve. B) The main forces acting on the 
valve during systole (when the valve is open) are shown. The fibrosa is compressed while the 
ventricularis is stretched and subjected to tensile bending stress. The ejection of blood from the 
ventricle exerts unidirectional laminar shear stress on the ventricularis (represented by the 
parallel blue arrows in the top panel and the single blue arrow in the lower panel). C) The main 
forces acting during diastole (valve is closed) are shown. Pressure (green arrows) exerted from 
cycling blood flow pulls the valve shut, and axial stress (purple arrows) seals the valve to prevent 
regurgitation. The fibrosa, the aortic side of the valve, experiences oscillatory shear stress 
(represented by the blue circling arrows in the top panel and the double-headed blue arrow in 




Integrins, focal adhesion complexes, and the cytoskeleton 
 Integrins are a superfamily of transmembrane cell adhesion receptors that have 
traditionally been known to bind to ligands at the cell surface, within the extracellular 
matrix, and within the cytoplasm. Integrins transduce signals from the extracellular 
environment to the cell interior; through this process, changes in the concentrations of key 
signaling molecules in the plasma are communicated to the cell. In addition, integrins have 
more recently been recognized as sensors of the mechanical environment surrounding the 
cell, which can result in changes in intracellular signal transduction pathways [67, 68]. 
Furthermore, integrins receive intracellular signals that regulate their ligand-binding 
affinity, fine-tuning the communication between the cell membrane and other cellular 
compartments [69]. By coordinating cues from the extracellular environment with 
intracellular signaling, integrins play an important role in cell adhesion, migration, 
proliferation, and survival.  
 The mechanism by which integrins transmit signals to the cell is dependent on their 
binding to the cytoskeleton [70]. Along with cytoskeletal proteins such as actin, many 
binding partners colocalize with integrins near the cell surface, forming complexes known 
as focal adhesion complexes [71, 72]. Focal adhesion proteins in these complexes mediate 
bidirectional mechanical transduction among integrins, external stimuli, and the cell [73]. 
Extensive research has found that integrin-focal adhesion complexes have the ability to 
sense forces important to the aortic valve, including cyclic stretch [74], shear stress [75], 
and hypotonic stress [76].  Integrin-focal adhesion complexes are also critical in signaling 
changes in the cell phenotype in response to mechanical stimuli and other cues, such as 
signals for cell and tissue remodeling [77, 78], cell proliferation and apoptosis [78, 79], 
and cell migration and angiogenesis [75, 80]. Integrins encompass only one of the families 
of mechanosensors, but the signals they transmit through focal adhesion complexes are 




G protein-coupled receptors (GPCR) 
 Similar to the other transmembrane proteins discussed above, GPCR bind to a 
variety of extracellular ligands to activate downstream signaling, namely through G-
protein activated signal transduction pathways [81]. These receptors have also been shown 
to be strongly sensitive to changes in flow across the surface of the endothelium [82]. Some 
research has demonstrated the specific methods of subunit recruitment utilized by the 
GPCR to become activated under mechanical stimuli [83], but the role of GPCR in the 
endothelium has not been fully realized in the vasculature or in the valve. Studies by Anger 
et al. showed that statins may partially inhibit inflammation in the aortic valve is through 
GPCR and their downstream effectors [84]. This work also demonstrated via array analysis 
that the extracellular regulated kinase (ERK) activation regulated by GPCR is highly 
upregulated in calcified human aortic valve tissue [84]. In addition, although the 
mechanism is unclear, statin therapy inhibits valvular expression of the GPCR regulatory 
proteins (RGS) [84]. While this initial data offer exciting directions for future targeted 
therapies, new insights have not been discovered. GPCR have known functions in many 
disease models [85], but their potential importance in the valve is not fully clear. More 
work must be conducted in this field to integrate these mechanical receptors into the 
lexicon of valvular mechanobiology. 
Glycocalyx 
 The large network of sugars embedded into the cell membrane consists of 
proteoglycans and glycoproteins, bound to long chains of carbohydrates called 
glycosaminoglycans (GAGs). These sugars provide a physical barrier between the blood 
and the endothelial cells [86, 87] and act as a “trap” where ions and other molecules in the 
blood may interact with membrane proteins [88]. The endothelial glycocalyx significantly 
changes in shape and height as a result of disturbed flow, possibly leading to changes in its 
function as a scaffold for signaling molecules [89]. Inflammation also plays a role in the 
deformation of the glycocalyx, possibly indicating a positive feedback between the 
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oscillatory flow and inflammation, which leads to upregulation of pro-inflammatory 
signaling pathways [90]. Specific studies of the glycocalyx in the valve endothelium show 
that pro-inflammatory mediators such as low-density lipoprotein (LDL) and 
immunoglobulins are more tightly bound to the sugar network in the valves of rabbits fed 
a high-cholesterol diet [91, 92]. The binding of these molecules to the glycocalyx is 
increased on the fibrosa endothelium, the aortic side of the valve more vulnerable to 
interstitial calcification. Investigative work by Sarphie [92] shows a the link between shear 
stress and the composition of the glycocalyx, which may alter the affinity of LDL particles 
for the cell surface and lead to infiltration and lesion formation. Of note, these studies have 
not been confirmed or improved for over a quarter century, leaving a significant gap in our 
understanding of the glycocalyx and its role in the valve. New technologies may prove 
useful in understanding this role and developing future therapies which may change 
glycocalyx stability and composition. In addition, although the characterization of the 
glycocalyx has not recently been studied in the valve, its extensive characterization in the 
vasculature may be easily translated to the valvular environment. With more work focused 
on this exciting area, we may discover a wide assortment of targets for therapeutic 




 Mechanosensitive genes in flow-mediated valve biology and dysfunction 
Shear stress is an important regulator of endothelial cell function.  The vascular 
endothelium has been widely studied in the context of shear stress, and a variety of vascular 
mechanosensitive genes have been discovered [66, 93-95]. However, little is known about 
the role of these mechanosensitive genes in the valvular endothelium. In this section, we 
review the genes that have been studied in valvular endothelial cells, including some 
exciting new opportunities in valve research based on findings in the vasculature. For 
reference, Figure 1.5 shows a summary of valvular mechanosensitive genes in both 
disturbed flow, as seen at the calcifying fibrosa, and laminar flow, as observed at the 
ventricularis.  
Figure 1.4 Major mechanosensors in valvular endothelial cells 
Integrins bind to the extracellular matrix to sense the dynamic mechanical environment 
surrounding the endothelial cell.  Ions and antibodies are trapped by the glycocalyx in the 
surface of the cell, which translates to various downstream signal transduction pathways. 
Cell adhesion molecules (CAMs), such as cadherins or PECAM-1, sense changes in the 
mechanical environment between cells due to shear stress or other mechanical stimuli. 
These mechanosensors transduce the changes sensed through diverse signaling cascades 
(represented by black arrows) and through the actin cytoskeleton, which ultimately leads 
to transcriptional changes. The function of G protein coupled receptors is not fully known 
in the valve but their role in vascular endothelium suggests that they play a role in sensing 





Transforming growth factor-β (TGF-β) ligand and receptors 
The TGF- β family of growth factors regulate a wide variety of cellular response 
such as growth, development, immune system regulation, and tissue homeostasis [96]. 
TGF- β signaling is initiated by the binding of TGF- β to TGF- β receptors type I and type 
II. These two receptors form a receptor heterocomplex that recruits and phosphorylates R-
Smad proteins. Different signal transduction pathways can be activated depending on the 
Smad protein complexes phosphorylated [97]. TGF- β activity increases more than 100-
fold in bovine aortic endothelial cells under shear conditions compared to static condition 
[98], suggesting that TGF- β plays a role in flow-induced vascular remodeling driven by 
fluid shear stress in the endothelium. 
Villar et al [99] found that in patients with aortic stenosis circulating plasma levels 
of TGF- β1, the most abundant isoform of the TGF- β family, were nearly three-fold higher 
than in healthy controls. Yetkin et al [100] studied patients with tricuspid calcified and 
stenotic aortic valves and found that the calcified valves presented similarly increased 
expression of TGF- β1. Furthermore, this work suggested a link between TGF-β1 and 
cysteine C, a cysteine protease inhibitor highly expressed in mature osteoblasts that inhibits 
bone resorption and appears in osteoblast differentiation [101, 102].  These findings show 
that high levels of the TGF- β cytokine in blood induce an endothelial cell inflammatory 
phenotype; thus, TGF- β and its receptors may play an important role in aortic valve 
calcification and in regulating AV endothelium function . TGF- β has also been found to 
promote endothelial-mesenchymal transition (EndMT); ovine aortic valve endothelial cells 
grown in the presence of TGF- β exhibited decreased levels of CD31 (an endothelial cell 
marker) and increased levels of α-smooth muscle actin [103].  
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The combined evidence from these studies ilustrates the importance of TGF-β in 
the events leading to CAVD.  Matrix production and endothelial phenotypic transformation 
are critical for the events leading to CAVD, and TGF-β is a critical regulator of these 
pathologies.  
Bone morphogenetic proteins (BMPs) 
BMPs are multi-functional growth factors that belong to TGF-β superfamily [104]. 
These proteins are physiologically observed in bone and initiate bone formation during 
development and in injury [105]. In vascular endothelium, bone morphogenic protein 4 
(BMP4) is upregulated by disturbed flow, leading to endothelial inflammation and 
ultimately dysfunction [105-107]. Additionally, in human atherosclerotic vasculature, both 
BMP2 and BMP4 expression are upregulated [105, 108]. Endothelial dysfunction and 
hypertension in mice infused with BMP4 has been observed [109], and BMP antagonist 
treatment protects against atherosclerosis [110, 111]. Endothelial cells in the aortic valve 
may secrete BMPs in response to changes in shear stress [112], and BMP expression of 
interstitial cells may be linked with age-related valvular degeneration [106]. Smad 1, 5, 
and 8 are downstream molecules in the BMP signaling pathway and have been associated 
with the onset of aortic stenosis [113]. Sucosky et al [65] studied porcine aortic valve 
leaflets exposed to physiological and altered shear-stress conditions for 48 hours ex vivo 
and found that BMP-4 and TGF-β were increased in pathologically altered conditions; 
these conditions stimulated endothelial inflammatory response demonstrated by an 
increase in adhesion molecule expression. These results were validated by Ankeny et al 
[54] in human calcified aortic valves and non-calcified AVs; calcified fibrosa presented 
higher Smad 1/5/8 phosphorylation and lower BMP antagonists (crossvienless-2/BMPER 
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and noggin). This data, in the valve and in other vascular tissues, strongly suggests the 
importance of the BMP signaling pathway in aortic valve calcification. 
Wnt/β-catenin 
 Wnt proteins are a family of secreted signaling glycoproteins used for short- or 
long- range signaling. They bind to receptors of the Frizzled family to regulate a wide 
variety of cellular processes such as cell fate determination, motility, stem cell renewal, 
and cell migration [114-116]. The Wnt/β-catenin pathway (also known as the canonical 
Wnt pathway) is widely known to regulate aortic valve formation and disease [117]. β-
catenin is a cytosolic protein that is bound to Wnt receptors in the cytosol and is degraded 
via ubiquitination in the absence of Wnt [118]. When Wnt binds to Wnt receptors, β-
catenin is stabilized and released to the cytosol, where it accumulates and translocates to 
the nucleus to activate the transcription of specific genes [114]. Shear stress has been found 
to regulate the canonical Wnt pathway in endothelial cells, leading to the increased 
expression of angiopoietin-2, a protein involved in vascular development and repair, in 
human aortic endothelial cells (HAECs) [119]. In patients with symptomatic aortic valve 
stenosis, modulators of the Wnt signaling pathway, including WIF-1, DKK-1, and sFRP-
3, exhibit increased expression in calcified aortic valves. Some modulators also positively 
correlate with valvular calcification, indicating their potential role as biomarkers of aortic 
valve stenosis [120]. Additionally, total levels of Wnt binding protein β-catenin have been 
found to be upregulated in human calcified aortic valves [121], calcified valves in a 
hypercholesterolemic rabbit model [122], and calcified valves in a hypercholesterolemic 
mouse model [123]. This evidence shows the importance of the Wnt canonical pathway in 
CAVD. No evidence directly linking the Wnt/β-catenin pathway and valvular shear stress 
has been found; however, the data obtained from HAECs indicates that the abnormal shear 




Notch signaling pathways 
Notch is a single transmembrane protein that, upon activation, releases a soluble 
Notch intracellular domain; this domain translocates to the nucleus and binds to specific 
sequences in the DNA to regulate gene transcription [124, 125]. The Notch signaling 
pathway plays a critical role in the development and homeostasis of the cardiovascular 
system [126]. While not directly working with the valve endothelium, Theodoris et al [127] 
studied the effect of shear stress in Notch1 (a single transmembrane protein of the Notch 
family) in endothelial cells. Notch1 haploinsufficient (Notch1+/-) and wild-type (Notch1+/+) 
IPSC-derived ECs were exposed to hemodynamic shear stress. The expression of more 
than 1,000 genes involved in osteogenesis, oxidative stress, and inflammation was 
dysregulated in the Notch1+/- cells, causing an osteogenic and inflammatory phenotype. 
Interestingly, in the aortic valve, overrepresentation of Notch1 missense variants correlates 
with increased prevalence of bicuspid aortic valve disease in human patients [128]. Notch1 
in the aortic valve interstitium has been found to repress the activity of Runx2, a 
transcription regulator of osteoblast cell fate [129]; therefore, decreased expression of 
Notch1 in the aortic valve may lead to accelerated valve calcification. While no known 
direct link relates the disturbed shear stress profile observed at the fibrosa with 
calcification, hemodynamic shear stress at the ventricularis may promote Notch1 activity, 
leading to an anti-osteogenic and anti-inflammatory endothelial phenotype that protects the 
ventricularis endothelium from dysfunction and calcification. 
Nitric oxide (NO) signaling and endothelial nitric oxide synthase (eNOS)  
Nitric oxide (NO)  is a soluble gas with a short half-life (up to 30 seconds) that is 
synthetized from the amino acid L-arginine by the constitutive calcium calmodulin-
dependent enzyme nitric oxide synthase (NOS) [130]. It is considered one of the most 
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important substances produced in the endothelium and plays a key role in inflammation, 
vasodilation, and oxidative stress [131]. Decreased NO biosynthesis facilitates vascular 
inflammation through an increase in lipoprotein oxidation [132].  Endothelial nitric oxide 
synthase (eNOS) is a shear-sensitive gene that is upregulated in laminar shear conditions 
(physiological conditions) and downregulated in low and oscillatory shear conditions 
(pathophysiological conditions) [133]. Bosse et al [134] studied the role of NO in aortic 
valve calcification using a co-culture system of endothelial cells and aortic valve interstitial 
cells (AVICs). The authors found that endothelial cells secrete NO which is absorbed by 
AVICs, preventing calcification through regulation of the Notch1 signaling pathway in 
AVICs.  Richards et al [53] found that, in both calcified and non-calcified human aortic 
valves, the ventricularis side exhibited three-fold higher expression of eNOS compared to 
the fibrosa. Interestingly, the calcified valves presented lower values of eNOS expression 
on both sides compared to healthy aortic valves. In the same study, in vitro experiments 
determined that endothelial secretion of NO decreases myofibroblastic activation, 
osteoblastic differentiation, and matrix calcification of valvular interstitial cells. El 
Accaoui et al [135] developed a mice model of aortic valve stenosis by knocking down 
eNOS. They found that 30% of these mice had bicuspid aortic valves and that these mice 
presented fibrosis and calcification at six and eighteen months of age. To further validate 
their work, El Accoui et al co-cultured porcine VICs with or without valvular endothelial 
cells, and they found that the endothelial cells inhibited profibrotic processes in VICs.  
This VIC study shows the importance of eNOS in valvular calcification and 
provides a clear mechanism linking decreased NO bioavailability to endothelial 
dysfunction and increased fibrosis and calcification. While NO has been investigated 
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previously as a therapeutic agent, stimulation of endothelial NO production and exogenous 
NO treatment in the valve still offers an avenue for potential therapy in aortic valve disease.   
Reactive oxygen species (ROS) 
ROS are partially reduced metabolites of oxygen that possess high oxidizing 
capabilities and act by damaging DNA and oxidizing lipid and cellular constituents [136]. 
They regulate cell growth, apoptosis, senescence, cell adhesion, and differentiation and are 
considered a key component in inflammatory diseases [137, 138]. One of the most 
important mechanisms in ROS production is the NADPH oxidase complex, which donates 
an electron to oxygen species in the cell to generate superoxide [139]. Both gene expression 
and protein levels of NADPH are increased four-fold in oscillatory flow in bovine aortic 
endothelial cells; this correlates with an increase of oxidized LDL through superoxide (O2
-
-) modification [140]. Under laminar shear stress, the ROS production in human umbilical 
vein endothelial cells (HUVECs) increases initially but  decreases back to baseline levels 
over time, demonstrating the complexity of ROS signaling in the endothelium [141]. Both 
superoxide and hydrogen peroxide expression are significantly increased in calcified 
regions of the valves; however, non-calcified regions, even in stenosed valves, present 
similar levels of superoxide and hydrogen peroxide as the tissue of healthy valves [142]. 
Finding key components in these pathways may be critical in creating a full picture of the 
pathological degeneration of the valve.  
ROS play a role further downstream of the endothelium; even in early stages of 
CAVD, valvular interstitial cells exhibit an accumulation of ROS, suggesting the role of 
ROS in disease development [143-145]. Branchetti et al [146] collected VICs from patients 
with and without CAVD and found that cells from stenosed patients had ROS-induced 
DNA damage and impaired DNA repair ability, which could be rescued with antioxidant 
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enzyme treatment. In a thorough study showing the direct role of ROS in the interstitium, 
Das et al [147] found that treatments decreasing ROS formation, specifically via decreases 
in the MAPK-TGF-β pathway, resulted in decreased calcium nodule formation. 
Throughout the valve, ROS are important contributors to CAVD both at the endothelial 
and interstitial cell layer, and changes in the oxidative state of the valve and the valvular 
endothelium may contribute significantly to pathological degeneration of the valve.  
Interleukins 
Interleukins are important inflammatory cytokines released from T lymphocytes, 
macrophages, monocytes, and endothelial cells; they bind to specific cell receptors and 
play a role in communication with leukocytes, cell growth, and differentiation [148, 149]. 
Interleukins produced in the endothelium play an important role in several diseases such 
as atherosclerosis, tumor development, and chronic infections [148, 150]. Pathological low 
shear stress facilitates the increased expression of interleukin-6 (IL-6) and interleukin-1 
(IL-1) from the endothelium, causing vascular smooth muscle cells to proliferate in early 
atherosclerotic plaques [151]. Interleukins also play a role in the valve:  IL-6 has been 
found to be involved in the development and progression of aortic valve disease by 
affecting EndMT [152]. In innovative studies, Mahler et al [153] utilized a three-
dimensional collagen gel to culture porcine aortic valve endothelial cells (PAVECs); they 
found that PAVECs underwent EndMT via the Akt/nuclear factor-κβ-dependent pathway 
when treated with IL-6 in a dose-dependent manner. Thus, IL-6 is a potent regulator of 
EndMT, which is a critical step in tissue dysfunction and ultimately valve calcification 
[154]. Moura et al [155] conducted a study in patients with asymptomatic moderate to 
severe aortic stenosis treated with or without rosuvastatin, a statin used to reduce total and 
LDL cholesterol [156];  the expression of IL-6 was measured in the patients before and 
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after the statin treatment. Patients treated with rosuvastatin exhibited a slowed progression 
of aortic valve stenosis and a five-fold decrease in the serum levels of IL-6, indicating 
reduced inflammation at the endothelial level. Interleukin-1 is expressed in the 
endothelium of atherosclerotic plaque and may be linked to atherogenic inflammation 
[157]. In the frame of aortic valve disease, IL-1 receptor antagonist deficient mouse were 
studied. These mice presented an increase in aortic valve thickness compared to wild type 
mice. T cells of the IL-1 receptor deficient mouse were analyzed and found to express 
much higher levels of tumor necrosis factor (TNF)-α compared to T-cells of wild-type mice 
This finding suggests that IL-1 may induce inflammation in aortic valve endothelial cells 
through TNF-α signaling pathway and that this inflammation may play a critical role in 
development of aortic stenosis [158].  These studies, in combination with those in vitro,  
show that abnormal shear stress, as experienced at the fibrosa, increases IL-6 and this 
interleukin, possibly coupled with others, promotes valve calcification.  
Kruppel-like factors (KLF) 
Kruppel-like factors (KLF) are members of the zinc-finger family of transcription 
factors which bind to DNA sequences including CACC-, GC- or GT- box elements in 
promoter and enhancer regions [159]. In the vascular endothelium, KLF2 has been widely 
studied; it is upregulated in high laminar unidirectional shear stress (physiological 
conditions) and downregulated in low oscillatory shear stress (pathophysiological 
conditions) [160-162]. In extensive in vitro experiments, human aortic valve endothelial 
cells (HAVECs) from non-calcified aortic valves exhibited higher KLF2 expression in high 
unidirectional shear stress (20 dynes/cm2, conditions similar to ventricularis) and lower 
expression in low oscillatory shear stress (±5 dynes/cm2, conditions similar to fibrosa); 
these studies support the idea that the ventricularis side shows higher KLF2 expression and 
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an anti-inflammatory phenotype [14]. To study inflammatory markers such as KLF2 in 
detail, Weinberg et al [163] created a computational model of aortic valve hemodynamics 
to mimic the exact shear profile experienced by the aortic valve. The simulated shear 
profiles were then applied to HUVECs, and the expression of KLF2 was found to be 
significantly higher in the cells that experienced the ventricularis shear profile. In 
microarray studies by our group, porcine aortic valve fibrosa showed decreased expression 
of KLF2 and KLF4, indicating the importance of KLF2 and KLF4 in valvular endothelium 
[14]. These initial studies may lead to important discoveries for these anti-inflammatory 
markers in valvular function and endothelial cell phenotype.  
KLF4 is another member of the KLF family that, when overexpressed, induces anti-
inflammatory and anti-thrombotic factors such as thrombomodulin and endothelial nitric-
oxide synthase; conversely, when knocked down, KLF4 induces inflammation [164, 165]. 
More importantly, KLF4 is known to be upregulated in vascular endothelial cells in laminar 
shear stress compared to oscillatory shear stress [166, 167].  So far, the role of this KLF 
protein in aortic valve calcification is unknown; however, a study conducted by Maleki et 
al [168] analyzed patients with bicuspid aortic valve (BAV), who are known to develop 
aortic valvular stenosis more rapidly than patients with tricuspid aortic valve (TAV), and 
found a significant decrease in KLF4 expression in the aortic region near the valve in BAV 
patients compared to TAV patients. The authors postulate that the disturbed flow generated 
by BAV is the primary contributor to this decreased KLF4 expression. Therefore, we 
expect that the same abnormal shear profile will be experienced by the valve and will cause 






 YAP and TAZ are effectors of the Hippo signaling cascade known to regulate 
several transcription factors that are key players in CAVD such as Runx2, SMADs, and 
PPAR [169]. These effectors have been studied in aortic valve interstitial cells where they 
have been correlated with osteoblastic differentiation [170]. Interestingly, changes in 
matrix stiffness, such as the ones observed during AV fibrosis, have been shown to affect 
translocation and activation of YAP which indicates a potential link between ECM 
degradation and osteoblastic differentiation [171]. This pathway has also been found to be 
flow-sensitive in the vascular endothelium where it was upregulated in disturbed flow 
conditions and its inhibition lead to decreased atherogenesis [172, 173]. However, the flow-
sensitive role of these effectors in the valvular endothelium is yet to be studied. 
Endothelial-to-mesenchymal transition (EndMT) 
 EndMT is defined as the process by which endothelial cells lose a portion of their 
cellular features and obtain characteristics of mesenchymal cells such as loss of tight 
junctions, increased motility and increased ECM secretion [174]. EndMT has been widely 
studied in the vascular endothelium and atherosclerosis where it has been shown that 
disturbed flow promoted EndMT and its inhibition reduced atherosclerosis progression 
[175]. Regarding EndMT in the aortic valve endothelium, changes in matrix stiffness, such 
as the ones observed in AV fibrosis, can induce EndMT [176]. Another study demonstrated 
that treatment of TNFα to valvular endothelial cells promoted EndMT [177]. Aikawa et al 
[178] studied the interplay between interstitial cells and endothelial cells demonstrating 
that VICs can help mitigate EndMT when in contact with VECs which reinforces the notion 
that the interplay between VECs and VICs is crucial for CAVD. The role of shear stress in 
EndMT in the aortic has not been fully studied however there has been a study by Butcher 
et al [179]that demonstrated that oscillatory shear stress increased markers of EndMT 
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(ACTA2, SMA, Snail and TGFβ1) in valvular endothelial cells while steady flow did not. 
This study does not delve in the mechanism by which EndMT is regulated by shear stress 
and opens interesting avenues for future studies to better understanding such a key step in 
CAVD pathogenesis. 
  
Figure 1.1.5 Mechanosensitive genes in the aortic valve endothelium  
A) TGF-β and BMP are mechanosensitive molecules that bind to their respective receptors 
and activate the SMAD signaling cascade by phosphorylating SMAD molecules, which 
ultimately translocate to the nucleus. Wnt molecules bind to frizzled Wnt receptors and 
cause the release of β-catenin (Wnt canonical pathway) which leads to cytosolic β-catenin 
accumulation and translocation to the nucleus. Interleukins bind to interleukin receptors 
and regulate the NF-κβ signaling cascade that alters gene transcription. All these pathways 
induce inflammatory and osteogenic gene transcription, leading to endothelial dysfunction. 
Inflammatory miRNAs are also upregulated in disturbed flow,causing gene translation 
repression of anti-inflammatory genes. NADPH is upregulated in disturbed flow, which 
induces the generation of ROS. B) KLFs are mechanosensitive genes upregulated in 
laminar flow that translocate to the nucleus and induce anti-inflammatory gene 
transcription. Notch1 binds to Notch receptors and causes NICD to be released and 
translocate to the nucleus, thereby promoting gene transcription. Anti-inflammatory 
miRNAs are upregulated in laminar flow, repressing translation of inflammatory genes. 
eNOS is upregulated in laminar flow and induces nitric oxide generation and release 
outside of the cell [5]. 
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 In vitro and in vivo models to study CAVD 
1.6.1 In vitro and ex vivo models of CAVD 
 One of the first and most characterized in vitro  models of shear stress is the cone-
and-plate viscometer [180, 181]. In this system, shear stress is applied to cultured cells in 
a stationary plate by a rotating cone. A modified version including a speed-controlled 
motor with variable rotational velocities was later introduced [182]. More recently, our lab 
has developed a modified cone-and-plate which is housed in a standard incubator; in this 
system, programmed shear stress profiles can be controlled by using a computer [183, 184]. 
Furthemore, in collaboration with Dr. Nerem and Dr. Yoganathan, we have developed a 
modified cone-and-plate viscometer that can be used with porcine AVs and can apply 
different shear stress profiles using a computer [15, 65, 185]. Another relevant porcine 
model for aortic valve calcification has been developed by Balachandran et al [71]. In this 
model, the effects of cyclic stretch were studied using porcine aortic valve leaflets in a 
unidirectional stretch bioreactor. Calcification increased significantly under higher stretch 
conditions, along with bone marker expression, cellular apoptosis, total calcium content, 
and alkaline phosphatase activity. These results correlate with those observed in human 
valve calcification and prove the utility of this model for the study of CAVD mechanisms 
and treatments.   
 Another in vitro model of shear stress is the parallel-plate flow chamber, developed 
originally by Frangos, McIntire, and colleagues [186, 187]. In this system, a flow chamber 
consisting of a polycarbonate plate, a rectangular Silastic gasket, and a glass slide (or cover 
slip) with the attached EC monolayer is held together by a vacuum maintained at the 
periphery of the slide. Additionally, novel shear stress system developed by Ibidi ® 
consists of two syringes connected to a slide with a channel where cells are plated; by 
applying different pressure to the syringes the system can generate various shear stress 
profiles. This system allows for long-term experiments in sterile conditions and for live 
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imaging as the only part of the system that needs to be in the microscope is the slide. 
Although these shear stress systems are the most commonly used in vitro  shear systems, 
microfluidic chambers are being used because they allow for high throughput experiments. 
This method was pioneered and commercialized by Schaff et al. [188-190]. More recently 
there have been new bioreactors that allow for more precise control of shear stress profiles 
and matrix composition and that have been used to study shear profiles in valvular 
endothelial cells such as the one developed by Butcher et al [179]. 
 
1.6.2 In vivo models of CAVD 
 To study CAVD in a controlled system, animal models of valvular dysfunction are 
utilized in a laboratory setting. The same principles used to diagnose CAVD in humans 
may be used to study the progression of the disease in animal models. Valvular cells 
extracted from bovine sources have been widely used because they are easy to extract and 
because the structure of the bovine aortic valve is similar to the human aortic valve [65-
67]. Porcine models have also been widely utilized for studies of the aortic valve, since the 
heart and cardiovascular system of the pig are really close in size to the human equivalents 
[68-70]. Furthermore, hypercholesteremia can be induced in rabbits by feeding them a high 
cholesterol (0.25%) diet for prolonged periods of time (12-16 weeks); this diet induces the 
development of atherosclerosis and aortic valve calcification [72-74].  Another interesting 
Figure 1.1.6 Models of flow and shear stress. 
A) Cone-and-plate viscometer. Adapted from Jo et al. (1991). B) Parallel plate flow 




in vivo model uses high cholesterol diets supplemented with Vitamin D2 in New Zealand 
Rabbits to increase transvalvular velocity and induce the presence of calcific nodules in the 
AV [191].  In each of the cases listed above, the cost of maintaining, breeding, and 
genetically modifying such large animals is often prohibitive. Thus, the mouse has been 
explored as a tool for further valve studies by our group and many others. 
 The mouse has been widely used to study aortic valve disease progression [192]. 
As wild-type (WT) mouse strains do not develop aortic valve calcification spontaneously, 
dietary and/or genetic modifications are necessary to induce AV disease. Commonly, mice 
deficient in the low-density lipoprotein (LDL) receptor (Ldlr−/−) are used. Ldlr−/− mice 
with only apolipoprotein B (ApoB)-100 (Ldlr−/−;-only) spontaneously develop mild 
hypercholesterolemia and reductions in valve orifice diameter (>50%); this leads to 
increased transvalvular systolic pressure gradients, and left ventricular hypertrophy at the 
age of ~1.5 years when fed with regular diet [193].  
 Typically, the Harlan Teklad TD.88137, or “Western” diet, is used in models with 
a dietary induction component [194]. Towler and colleagues first reported extreme 
hyperlipidemia (~1040 mg/dL), hyperinsulinemia/hyperglycemia, and mineral deposition 
in Ldlr−/− mice fed Western diet for 16 weeks [195]. Ldlr−/− mice fed a similar high-
cholesterol diet (0.15%) develop increased valve thickness, macrophage accumulation, 
superoxide production, activated myofibroblasts and osteoblasts, and mineralization[196]. 
When mice are regularly exercised while being fed a high-cholesterol diet, these 
pathological symptoms are significantly reversed [196]. Another recent study by Scatena 
et al [197] in LDL-/-ApoB100/100 showed that use of diabetogenic and pro-calcific diet 
induced endothelial dysfunction, inflamed and calcified thickened aortic valve cusps 
mimicking CAVD features found in patients with type II diabetes mellitus. 
 Most interestingly, other diets, such as the high-fat, low-cholesterol diet are able to 
induce early markers of CAVD even in WT mice; thickened leaflets, black particulates 
which may be von-Kossa-positive phosphate staining, decreased aortic valve opening area, 
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and increased transvalvular blood velocities are reported, along with CD68-positive 
macrophage and T-lymphocyte infiltration into the valvular interstitium [198].  
 In addition to the Ldlr−/− model, a second common genetically manipulated model 
is the endogenously hyperlipidemic [199] ApoE-deficient (Apoe−/−) mouse [200, 201]. 
ApoE allows receptor-mediated removal of very-low density lipoprotein (VLDL) from 
circulation. ApoE also regulates T-cell proliferation and macrophage function, and it 
modulates lipid antigen presentation as well as general levels of inflammation and 
oxidation [202]. Apoe−/− mice fed with regular diet develop hypercholesterolemia 
(~490 mg/dL) [203], and when aged (~2.5 years) they present increased transvalvular 
velocity, mild aortic regurgitation, SMA and osteocalcin (OCN) expression, macrophage 
and T-cell infiltration, and nodular calcification [204]. Administration of the “Western  
diet” to Apoe−/− mice for four to five months induces accelerated early disease, with a 
substantial increase in serum cholesterol (up to ~588 mg/dL), thickened leaflets, activated 
endothelial cells, and subendothelial lesions rich in macrophages (colocalized with MMP-
2/9, cathepsin B, SMA, ALP, Runx2, and OCN expression) [205, 206]. Importantly, there 
is no evidence of calcification at this early time point, though a bisphosphonate-conjugated 
imaging particle shows signs of early microcalcification that colocalizes with cathepsin K 
[205, 206].  
 Along with these two commonly used hyperlipidemic models, other interesting 
genetic models that mimic some aspects of CAVD exist. Knockout of the mineral-binding 
ECM protein matrix GLA protein (Mgp−/−) produces spontaneous ectopic apatite 
formation in the arterial collagen fibrils and von-Kossa-positive calcification in the aortic 
valve [207]. In addition, an insufficiency of elastin (Eln+/−) produces proliferation of VICs 
and aortic regurgitation [208]. Hypomorphic expression of fibulin-4, an ECM stabilizing 
protein, results in thickened leaflets and significant functional impairments, as well as 
positive pSmad2, pSmad1/5/8, and von Kossa staining [209]. Mice deficient in the anti-
inflammatory cytokine interleukin-1 receptor antagonist (Il1rn−/−) are particularly 
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important in studying the onset of CAVD. These animals develop thickened aortic valves 
infiltrated by macrophages and differentiated myofibroblasts when aged, Il1rn−/− mice 
develop calcified lesions with functional impacts on transvalvular blood velocity [158]. 
Endothelial nitric oxide synthase 3 (eNOS) knockout mice supplemented with a 
cholesterol-enriched diet with Vitamin D2 (25,000 IU, daily) have been shown to present 
microcalcifications in the aortic valve sinus in just three months[210]. Furthermore, we 
have been working on a novel transgenic GATA5 knockout mouse; 15% of this mouse 
strain has been shown to present bicuspid aortic valve phenotype [211]. As previously 
stated, BAV patients present AV calcification at an earlier age [28]. We want to capitalize 
on this phenomenon by combining it with hypercholesterolemia to develop an accelerated 
model of AV calcification.  
 Various techniques may be used to measure murine aortic valve function, including 
ultrasound, magnetic resonance imaging (MRI), catheterization, and ex vivo tissue staining. 
Overall, MRI is the best technique in assessing the degree of aortic stenosis because it 
causes no injury to the animal and gives information about valve morphology, severity of 
stenosis and anatomy and function of the heart. Unfortunately, MRI is expensive and 
requires a high level of sedation. Additionally, catheterization is a powerful technique, but 
it requires the mice to be fully sedated and may cause internal injuries [75]. To confirm the 
extent of leaflet calcification, post-mortem sectioning of the aortic valve and staining with 
dyes such as Alizarin red [76, 77] or von Kossa stain [71, 78] is required. However, to 
harvest the heart and vasculature, the animal must be sacrificed, and disease progression 
cannot be monitored. Due to these limitation, ultrasound echocardiographic imaging is 
most widely used. This method conveys the same information as MRI with less precision.  
However, the advantages of echocardiography are low levels of sedation required (which 
decreases the likelihood that the method may interfere with the biological study) and the 
relatively low cost of the imaging.  
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 Our group and others have proven the utility of echocardiography in assessing the 
status of aortic stenosis in mice. Two images obtained with echo are shown below. The left 
panel of Figure 1.7 shows the peak aortic valve velocity for a young (2 months of age) 
ApoE-/- mice; a peak velocity of 900 mm/s can be observed. The right panel shows the 
peak aortic valve velocity for aged ApoE-/- (15 months) mice with three months of high- 
fat diet; the peak velocity is much higher (in the range of 2200 mm/s) indicating that the 
aortic valve is stenosed. Post-mortem calcification staining on these leaflets showed that 
valves with severe stenosis have calcification nodules on the leaflets and the aortic valve 
root. Mice with no stenosis present non-calcified valves and non-calcified root. 
 
 
1.6.3 Computational Models of CAVD 
 Alternative models including several powerful computer imaging techniques are 
being increasingly used to visualize the dynamics of valve function and dysfunction. A 
recent study by Weinberg et al [79, 80] proposes a computational model for the aging aortic 
valve that varies the leaflet thickness and extensibility from data obtained experimentally. 
Progression of CAVD is modeled by adding calcified zones to the valve. The sites of 
calcification initiation are the regions of high flexure; these regions show preferential 
Figure 1.7 Echocardiogram of healthy and diseased mouse aortic valve. The left 
panel shows the aortic valve velocity of a young, healthy mouse (900mm/s) while the 




calcification formation in explanted aortic valves. This model can predict how the peak 
velocity in the aortic valve and the aortic valve area evolve over time. A comparison 
between the model by Weinberg et al and experimental data [81] showed a good correlation 
between the two, proving the utility of computational models for the study of the disease 
progression. This study can be used clinically to predict degradation of valve function and 
to determine the best tissue parameters to target in order to diminish the rate of 
calcification. The data from this paper could also be used to create in vitro and in vivo 
models that mimic specific phases of CAVD. These modes could be used to better study 
the different pathologies experienced in the valve can be better studied. Engineered and 
computer models of valve function and dysfunction have been expansive and 
comprehensive, giving us new insights into the hemodynamics of CAVD and offering 
novel tools for future research.  
 MicroRNAs and CAVD 
1.7.1 Biogenesis of miRNAs 
 microRNAs (miRNAs) are a large class of evolutionarily conserved, noncoding 
RNAs typically 18 to 22 nucleotides in length. miRNAs primarily function as post-
transcriptional regulators by interacting with the 3’ untranslated region (3’ UTR) of 
specific target mRNAs in a sequence-specific manner[212, 213]. A single miRNA can 
target hundreds of mRNAs. Pri-miRNAs are transcribed by RNA polymerase II and can 
be derived from individual miRNA genes, from introns of protein coding genes, or from 
polycistronic transcripts that often encode multiple closely-related miRNAs. Pri-miRNAs 
are then processed in the nucleus into pre-miRNAs by the RNase Drosha, pre-miRNAs are 
70–100 nucleotides hairpin-shaped precursors. Following transport to the cytoplasm, the 
pre-miRNA is further processed by the RNA endonuclease Dicer to produce a double-
stranded miRNA. The fully processed miRNA duplex is then incorporated into a 
multicomponent protein complex known as an RNA-induced silencing complex (RISC). 
During this process, one strand of the miRNA duplex is selected as a mature miRNA while 
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the other strand, known as miRNA*, is rapidly removed and degraded[214-217]. As part 
of the RISC, miRNAs negatively regulate gene expression through translational repression 
or mRNA cleavage, depending on the degree of complementarity.  
1.7.2 Role of miRNAs in CAVD 
While the role of mechanosensitive miRNAs in atherosclerosis is well-established 
[218], their role in AV biology and disease is only beginning to emerge [5, 219]. To identify 
mechanosensitive miRNAs in the AV endothelium, we conducted a miRNA array study in 
human AVECs (HAVECs) exposed to steady flow conditions (LS, unidirectional laminar 
shear) and d-flow conditions (OS, oscillatory shear). Additionally, we categorized the well-
known miRNAs according to their cellular function (Fig. 1.9A) [14]. We also carried out 
Figure 1.8 Biogenesis of miRNAs 
Adapted from Barca-Mayo (2012) [4] 
36 
 
an ex vivo array study using endothelial-enriched RNAs obtained from the fibrosa and 
ventricularis of healthy porcine aortic valves (PAVs) to identify side-specific miRNAs 
(Fig. 1.9C) [220]. These studies revealed ~30 shear-sensitive and ~24 side-specific 
miRNAs [14, 220], and using systems biology analyses we prioritized the list based on 
potential importance in CAVD (Fig. 1.9B). For coding genes (mRNAs), identifying the 
differentially expressed genes (>1,000) in various disease conditions such as 
atherosclerosis and cancer has become routine through gene array or RNA-Seq.  
 
The real challenge continues to be identifying those genes that play critical roles in 
the disease. While systems biology analyses and large-scale functional studies (such as the 
one we recently developed using a drosophila model [221]) have been incredible helpful, 
selected genes must still be studied in detail individually. The miRNA (~2,000 in humans) 
field faces an identical challenge. Recently, we published about the role of miR-214 in 
A B C 
483-3p 
Figure 1.9 Shear-sensitive miRNAs in HAVECs and side-specific miRNAs in Porcine 
AVs 
A)  Top shear-sensitive miRNAs in HAVECs comparing fibrosa exposed to OS (FO) with 
ventricularis exposed to LS (VL). B) Categorization of the well-known shear-sensitive 
genes from our array according to potential cell function. C) Top side-specific miRNAs 
comparing fibrosa and ventricularis from porcine AVs. 
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shear-dependent AV calcification, and began to work on two of the most exciting miRNAs 
so far: miR-181b and miR-483-3p (referred as miR-483). MiR-214 expression is 
upregulated in the fibrosa endothelium (compared to the ventricularis) and in response to 
OS conditions (compared to LS). miR-214 also regulates TGF-β1 in porcine AVs [220]. 
Interestingly, M1 macrophages can promote AV calcification by delivering miR-214 via 
micro-vesicles [222]. miR-125b is also upregulated in stenotic AVs compared to controls, 
and it regulates chemokines in diseased valve macrophages[223]. In contrast, Nigam et al 
identified miRNAs differentially expressed in aortic stenosis versus aortic insufficiency 
(miR-26a, -30b  and -195) in vivo using whole human BAV tissue samples. They also 
linked these miRNAs to calcification-related genes in VICs, such as SMAD1/3, Runx2,  
and BMP2 [224]. Similarly, Wang et al [225]  conducted miRNA arrays in healthy and 
diseased valves; these arrays provide a huge variety of novel miRNAs that can be potential 
therapeutic targets for CAVD. In another study, miR-141 was shown to be significantly 
decreased in BAVs and to regulate BMP2 [226]. Also, MALAT1, a long non-coding RNA 
implicated in other cardiovascular diseases, was shown to silence miR-204, leading to 
increased osteoblastic differentiation in human aortic VICs (HAVICs) via upregulation of 
SMAD4 and Runx2 [227, 228]. Another study showed that miR-486 and miR-204 are the 
top up- and down-regulated miRNAs respectively in diseased valves compared to controls.  
These two miRNAs play also a role in osteogenic differentiation of VICs [229]. Several 
new miRNAs have been recently shown to mediate AVIC calcification. miR-29b induces 
AVIC calcification via SMAD3 signaling [230], miR-204-5p promotes osteoblast 
differentiation via Runx2 upregulation [231], and miR-449c-5p [232] inhibits VIC 
osteogenic differentiation by silencing SMAD4. Recently, other studies have also 
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examined the role of miRs in CAVD: miR-616 regulates PON1 expression in CAVD 
tissues [233], miR-29b promotes calcification by activating the WNT/β-catenin pathway 
in VICs [234], miR-92a is upregulated in calcified bicuspid valves and serves as a novel 
biomarker [235], and miR-195 promotes interstitial calcification in bicuspid valves via 
SMAD7 targeting [236].  
These results demonstrate that several mechanosensitive and side-dependent 
miRNAs are associated with CAVD; however, miRNAs have yet to show a significant 
therapeutic potential to prevent or inhibit CAVD. The miRNA field in AV biology and 
CAVD is still in its infancy, and more studies by numerous groups are needed. For instance, 
because numerous investigators worldwide study cardiovascular disease (CVD) and 
cancer, many miR mimics (gain of function) and miR inhibitors such as anti-miRs (loss of 
function) are now being tested in clinical trials for cancer and CVD. 
1.7.3 miRNAs in the Clinic  
Given the increasing number of in vivo studies using miRNAs, some miRNA 
studies have moved into clinical trials. These miRNAs include anti-miR-122 (both LNA 
modified and galactose conjugated), anti-miR-103/107 (galactose modified), anti-miR-155 
(LNA), miR-29 mimic, miR-16 mimic, and miR-34 mimic [237].   
Anti-miR therapies 
The first anti-miR therapy was the LNA-modified anti-miR-122, a 15-nucleotide 
antisense RNA oligo complementary to the 5ʹ end of miR-122. This anti-miR is known as 
Miravirasen and is intended for the treatment of Hepatitis C Virus (HCV). Preclinical 
studies in rodents and in non-human primates indicate that Miravirasen passively 
accumulates in the liver, decreases cholesterol accumulation, and reduces titers of HCV 
[238-240].  A Phase I clinical trial was initiated in 2009 and no adverse reactions were 
reported; thus a Phase II trial was launched. In the first Phase II Trial, nine patients were 
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enrolled in four groups. Each patient received a dose of three, five, or seven mg/kg 
Miravirsen or placebo once a week for five weeks. Patients who received Miravisen 
experienced a significant dose-dependent reduction in HCV load and serum cholesterol 
levels. [241]. However, a more recent follow-up study showed mutations near the end of 
the 5ʹ UTR of HCV viral RNA in both in vitro samples and in clinical samples [242].  
Furthemore, RG‑101 (Regulus Therapeutics), is a N-acetyl-D-galactosamine 
(GalNAc)-conjugated anti-miR against miR‑122. RG-101 has also undergone Phase I trials 
in HCV-infected patients at a single dose of two–four mg per kg. Furthermore, Phase II 
trials have combined RG‑101 with direct-acting antivirals such as Harvoni (a combination 
of ledipasvir and sofosbuvir, see Regulus Therapeutics, press release dated 7 June 2016). 
However, this Phase II trials were put on hold by the US FDA after a second case of 
jaundice was reported (see Regulus Therapeutics, press release dated 1st Nov 2016). 
Additionally, RG‑125, a GalNAc-conjugated antimiR against miR‑103/107, 
recently entered clinical trials for the treatment of non-alcoholic fatty liver disease. 
Furthermore, miR‑103/107 expression is increased in the liver of obese mice, and it 
promotes diabetes progression by targeting caveolin 1, a protein involved in insulin 
signaling. Therefore, miR-103/107 is also being investigated at the pre-clinical stage in 
mice [243]. Finally, LNA-based anti-miR‑155 (MRG‑106; miRagen Therapeutics) has 
recently entered clinical trials to treat patients with cutaneous T cell lymphoma. 
miR-mimic therapies 
In addition to anti-miRs, miRNA mimics have also entered clinical trials. One of 
the most advanced miRNA mimics is MRX34, a miR‑34 mimic by Mirna Therapeutics. It 
is encapsulated in a lipid carrier called NOV40. Preclinical studies of mice treated with 
MRX34 nanoparticles showed an accumulation of miR‑34 in tumors, with significant 
tumor regression [244-247]. MRX34 entered a multicenter-phase I trial in 2013 in patients 
with primary liver cancer, small cell lung cancer, lymphoma, melanoma, multiple 
myeloma, or renal cell carcinoma. The trial included a dosage via intravenous infusion 
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either twice per week or five times per day. At the end of the trial, analysis of white blood 
cell samples showed significant reduction in miR‑34 target mRNAs FOXP1 and BCL2. 
However, the trial was terminated due to patient deaths (see Mirna Therapeutics Halts 
Phase 1 Clinical Study of MRX34) [248]. 
In addition, miR-16 mimics have entered Phase I Trials for patients with malignant 
pleural mesothelioma in a collaboration between EnGeneIC and the Asbestos Diseases 
Research Institute of Australia. miR‑16 was delivered in a nanoparticle with EGFR 
antibody surface conjugation to facilitate targeting to the tumor site. Preliminary data 
reported manageable safety in response to infusion of five billion nanocells loaded with 
1.5μg of miR‑15/16 mimics as a first dose level in the five enrolled patients [249]. Finally, 
two Phase I clinical trials of the miR‑29 miRNA mimic MRG‑201 (miRagen Therapeutics) 
have been started in patients with scleroderma.  
Although a considerable number of studies involving miRNA therapeutics 
have been conducted over the years, only a small number of miRNA therapeutics have 
moved into clinical development. The biggest challenges in developing miRNA-based 
therapeutics is maximizing stability and minimizing off-target effects. 
 MiR-181b in CAVD  
miR-181 family members contain four highly conserved mature miRNAs: miR-
181a, -181b, -181c, and -181d. These miRNAs are independently-derived from six 
precursors located on three different chromosomes: miR-181a-1 and -181b-1 are located 
on chromosome 1; miR-181a-2 and -181b-2 are located on chromosome 9; miR-181c and 
-181d are located on chromosome 19. miR-181b-1 and -181b-2 are identical in their mature 
sequences but are located on different chromosomes [250].  
The role of miR-181b is not yet clear. It has been previously studied in the 
endothelium by Sun et al [251], who showed that miR-181b was a protective miRNA that 
prevented inflammation by inhibiting NF-κβ activation via silencing of importin-α3. 
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Another study by Feinberg et al [252] showed that delivery of miR-181b mimic in obese 
mice lead to decreased endothelial dysfunction and increased expression of eNOS in 
adipose tissue ECs. Our group recently showed that miR-181b is one of the top shear-
sensitive miRNAs in valvular endothelium and is upregulated in OS conditions compared 
to LS conditions [14].  Due to the its high shear-sensitivity and unclear role in valvular 
endothelium, we have decided to further study the role of miR-181b in the valvular 
endothelium, and will this be the focus of the aim one of this dissertation. 
 ECM degradation and TIMP3 in CAVD  
The organization of the extracellular matrix (ECM) in the AV is crucial in ensuring 
the proper opening and closing of the valve throughout a cardiac cycle. ECM remodeling 
is one of the hallmarks of CAVD because it is linked to fibrosis, an intermediate step in 
CAVD[253]. The major proteinases involved in ECM degradation are matrix 
metalloproteinases (MMPs), include collagenases, gelatinases, stromelysins, matrilysins, 
membrane-type MMPs, and others [254], and ADAMTS (a disintegrin and 
metalloproteinase with thrombospondin domains) metalloproteinases [255]. The 
membrane-anchored ADAM metalloproteinases affect cellular behavior by proteolytically 
releasing the extracellular domains of cell surface molecules, such as membrane-bound 
growth factors, cytokines, and cell adhesion molecules. Interestingly, MMPs are 
upregulated at calcification areas in diseased AVs [256]. However, MMP regulation in 
CAVD conditions is unknown, and while MMPs have been previously studied in 
atherosclerosis and several cancers, their role in CAVD has not been defined yet [257, 
258]. MMPs are known to degrade extracellular matrix (ECM) in tumor metastasis, 
allowing for cell migration, infiltration, and growth. ECM remodeling has been previously 
studied in the context of aortic valve stenosis and calcification [259-262] but the specific 
role of MMPs and their regulation are yet to be discerned. 
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Tissue inhibitor of metalloproteinases (TIMPs) are inhibitors of matrix 
metalloproteinases (MMPs) and of disintegrin-metalloproteinases such as ADAMS or 
ADAMTSs. The mechanosensitive TIMP3 is especially interesting to our group because 
we have recently shown that it can be regulated by miR-712 in mouse endothelium. 
Additionally, treatment of mice with anti-miR-712 leads to decreased matrix remodeling 
and atherosclerosis by increasing TIMP3 levels [263]. Another study showed that TIMP3 
blocks the binding of VEGF to VEGF receptor-2 and inhibits downstream signaling and 
angiogenesis in the endothelium [264]. However, our group is the first to demonstrate that 
TIMP3 is shear-sensitive in valvular endothelium and side-specific in human AVs and that 
it plays a role in shear-sensitive valvular ECM remodeling [265]. 
 MicroRNA miR-483 in CAVD  
miR-483 is an intronic miRNA located in insulin-like growth factor 2 (IGF2). IGF2 
is a fetal growth factor that is involved in development and fetal growth [266]. miR-483-
3p has been previously studied in the cancer field. It was found to be upregulated in the 
plasma levels of patients with pancreatic cancer [267],  to suppress apoptosis in squamous 
cell carcinomas [268] and hepatocellular carcinomas [269], and to increase proliferation 
and migration in esophageal squamous cell carcinoma [270]. miR-483 has also been 
studied in smooth muscle cells, where it was found to be downregulated by treatment with 
angiotensin 2 and to regulate four targets of the renin-angiotensin system: AGT, ACE-1, 
ACE-2, and AGTR2 [271]. Additionally,  miR-483 circulating levels were significantly 
upregulated in heart failure patients after treatment with a left ventricular assist device to 
improve flow in the heart [272]. 
In the endothelium, the role miR-483-3p is still unclear. It has been shown to be a 
protective miRNA suppressing Endothelial-to-Mesenchymal (EndMT) transition in 
Kawasaki disease patients via silencing of the pro-EndMT gene CTGF [273]; on the other 
hand, miR-483 has also been shown to induce endothelial progenitor cell dysfunction, and 
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in vivo its silencing leads to faster thrombus resolution in venous thrombosis [274]. We 
hypothesize that miR-483-3p is a shear-sensitive and side-specific miRNA in valvular 
endothelium that inhibits endothelial dysfunction and calcification in the aortic valve by 
modulating the UBE2C/pVHL/HIF1α pathway. 
 Role of UBE2C and HIF1α in CAVD  
The ubiquitin proteasome pathway is a critical degradation mechanism for most 
short-lived proteins in eukaryotic cells. Ubiquitination is controlled by a series of ubiquitin 
ligase enzymes, which are composed of E1 (ub activator), E2 (ub conjugator),  and E3 (ub 
ligase)[275].  
UBE2C (also known as UBCH10) is one of ~30 E2 family members. It binds to the 
anaphase-promoting complex (APC/C), inducing lysine-11 (K11) monoubiquitination on 
substrates. These monoubiquitinated protein will be recognized by the APC/C complex, 
and aided with another E2 ligase (Ube2s). The monoubiquitinated proteins will be 
polyubiquitinated and sent for proteosomal degradation [276, 277]. The APC/C complex 
mainly regulates progression through the mitotic phase of the cell cycle and to control entry 
into the S phase [278]; however, recently APC/C has been shown to also play a role in 
other cell functions such as hypoxia [279], apoptosis [280], senescence [281], autophagy 
[282], or metabolism [283]. Of special interest to us is the role of APC/C in hypoxia 
because APC/C targets Von Hippel-Landau protein (pVHL), which is a E3 ubiquitin ligase 
known to target hypoxia-inducible factor 1α (HIF1α) for proteasomal degradation [279, 
284]. HIF1α is a transcription factor induced in hypoxia [285], cancer [286], and disturbed 
flow conditions [287]; it upregulates expression of genes (Fig. 1.10) such as TWIST11 
(EndMT regulator), VEGF (angiogenesis regulator), RUNX2 (osteoblastic differentiation),  




 HIF1α is regulated in a two-step process: prolyl hydroxylases (PHDs) modify 
HIF1α with hydroxyl groups [289], which are then recognized by pVHL and sent for 
proteasomal degradation (Fig. 1.11). 
 
Figure 1.10 Target genes of HIF1α 
Adapted from Yu et al (2017) [2] 
Figure 1.11 Regulatory mechanism of HIF1α 
Adapted from Wilson et al (2014) [3] 
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 Previous literature has shown that UBE2C and HIF1α are activated in numerous 
cancers including breast [290, 291], bladder [292, 293],  and colon cancer [294, 295]. 
Therefore, we hypothesize that UBE2C plays a role in HIF1α upregulation via degradation 
of pVHL. Importantly, HIF1α has been linked to CAVD [296], and many of the gene 
targets of HIF1α are known to mediate key CAVD pathogenic pathways: inflammation 
(TNFα, IL6) [297], EndMT (snail) [298] , fibrosis (TGF-β1), and osteogenesis (Runx2 and 
VEGF) (See Fig. 1.10).  
Due to the important role of HIF1α in cancer development, several therapeutic 
agents have been developed and are currently in clinical trials for various cancers. EZN-
2968 is an antisense nucleotide inhibitor that has been studied in patients with refractory 
solid tumors and it was found that administration of this drug via IV infusion for 6-weeks 
lead to decreased levels of HIF1α mRNA and protein as well as some of its target genes 
however, due to non-research related complications, the trial ended before any changes on 
tumor size could be assessed [299]. Of special interest to us is PX478, a water-soluble 
chemical inhibitor of HIF1α, that modulates mRNA and protein levels of HIF1α 
independent of oxygen levels of pVHL levels and that has been tested in a phase I clinical 
trial in advanced lymphoma tumor patients [300, 301]. Since there exist numerous FDA 
approved or emerging cancer drugs that target the HIF1α pathway and UBE2C, some could 
be repurposed as anti-CAVD drugs. 
 
A substantial portion of this chapter was published in: 
1. Fernandez Esmerats J, Heath JM, Jo H: Shear-sensitive genes in aortic valve 
endothelium. Antioxid Redox Signal 2015. 
2. Fernandez Esmerats J, Heath JM, Rezvan A, Jo H: Hemodynamics and 
Mechanobiology of Aortic Valve Calcification, Biomedical Engineering: Frontier 




2 SPECIFIC AIMS AND HYPOTHESES 
 Significance and Impact 
  Because of an increasing aging population in the US and other developed 
countries, CAVD has become a major cause of cardiovascular deaths [10, 302]. The main 
treatment alternatives for CAVD patients are AV repair or replacement by surgical or 
transcatheter methods [9, 10];  presently, no pharmacological treatment options are 
available. This is in large part due to a lack of mechanistic understanding of the disease; 
therefore, there is an urgent need for 1) a better understanding of the molecular mechanisms 
of CAVD, and 2) the development of therapeutics to prevent, slow down, and/or reverse 
the disease by targeting key molecular players. 
 MicroRNAs have emerged as key regulators of cell phenotypes and diseases. 
Multiple studies have been conducted to specifically study the role of mechanosensitive 
miRNAs in CAVD (Ch. 1.7.2). However, prior to this project, there were no studies on 
miR-181b or miR-483 in valvular endothelium, or investigations into these miRNAs as 
potential therapeutic targets for CAVD. Studying the specific role of miR-181b and miR-
483 may lead to new therapies to help prevent and treat CAVD.  
 Additionally, accelerated animal models to test therapies developed in vitro and ex 
vivo are needed. To this end, we have developed an accelerated animal model by combining 
GATA5 knockout mice, known to develop bicuspid AV, with our new 
hypercholesterolemic animal model via PCSK9-AAV injection. Bicuspid AV is one of the 
major risk factor for CAVD and is known to accelerate the development in CAVD in 
human patients [43]. When we combine bicuspid AVs with hypercholesterolemia in mice, 
we can induce AV sclerosis and calcification in just four months. This model will provide 
a faster and more clinically translatable tool for researchers across the world to test new 




 We have identified miR-181b and miR-483 as two novel, shear-sensitive miRNAs 
in the valvular endothelium conserved in mammalian species. miR-181b has been 
previously studied in cardiovascular diseases such as atherosclerosis [303] or aneurisms 
[304], as well as in cancer in mice and humans [250, 305]; however, the role of miR-181b 
in the valvular endothelium was unknown. Furthermore, Aim 1 established that miR-181b 
controls valvular ECM degradation, a key precipitating event in CAVD,  by controlling 
MMP activity via silencing of TIMP3.  
 Although miR-483 has been previously studied in the cancer field as well as in 
Kawasaki disease patients [273], its role and shear-sensitivity in the valvular endothelium 
were unknown. The focus of Aim 2 is to demonstrate its shear-sensitivity and its role in 
endothelial biology and AV calcification. miR-483 shear-sensitivity was shown to be 
controlled by the well-known shear-sensitive transcription factor KLF2[5, 66]. We also 
established that miR-483 controls inflammation and EndMT in the valvular endothelium 
via regulation of the E2 ligase UBE2C. In addition, we found that UBE2C ubiquitinated 
pVHL, which lead to activation of HIF1α and the transcription of its target genes. 
Furthermore, we conducted ex vivo therapeutic studies with miR-483 mimic and a FDA 
approved chemical inhibitor of HIF1α (PX478) and found that these two treatments lead 
to a significant decrease in AV calcification. 
 Last, we are interested in developing an accelerated animal model of CAVD 
because this field is lacking a fast and reliable animal model for mechanistic and 
therapeutic studies. To this end, we will be working with GATA5 knockout mice known 
to develop bicuspid AV phenotype in ~15% of mice. Combining BAV, a known risk factor 
for CAVD in humans, with hypercholesterolemia, via AAV-PCSK9 injection and high-fat 




 The finding that miRNAs are induced by disturbed blood flow is relatively recent 
and is supported by both in vitro studies in ECs and limited in vivo studies in mice [66, 
306]. However, the mechanisms by which miRNAs can lead to CAVD are still not fully 
understood. Although some miRNAs have already been implicated in CAVD[14, 15, 231, 
233], there have been no previous studies of miR-181b or miR-483 in valvular endothelium 
and CAVD. Our innovative study linking miR-181b to ECM degradation via TIMP3 
degradation introduces a novel mechanistic pathway for shear-induced matrix remodeling 
in AV endothelium. 
 Due to the lack of extensive research surrounding miR-483 in ECs, investigation of 
its potential target genes and functional changes with anti-miR-483 or miR-483 mimics 
will be crucial to understanding its role in the endothelium. Modulation of miR-483 in vitro 
has given important insight into the role miR-483 plays in EC inflammation and EndMT. 
Results from these studies indicated that miR-483 regulates inflammation and EndMT by 
silencing the E2 ligase UBE2C. We also identified a novel mechanistic pathway in which 
UBE2C upregulates HIF1α and its target genes by ubiquitinating and degrading pVHL, a 
E3 ligase that is responsible for HIF1α degradation. Our ex vivo calcification studies 
showed that induction of miR-483 using a mimic or inhibition of HIF1α using a chemical 
inhibitor (PX478), significantly decreases AV calcification in porcine tissues. 
 Furthermore, we have developed an accelerated animal model of CAVD by using 
GATA5 knockout mice and inducing hypercholesterolemia via AAV-PCSK9 
injection[307]. These mice present bicuspid AV phenotype at a rate of ~15% and combined 
with hypercholesterolemia, AV fibrosis and calcification can be induced in four months.  
 Project Objective 
 We know that laminar, unidirectional flow upregulates protective genes and 
downregulates “pro-CAVD” genes while disturbed flow results in the opposite 
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phenomenon; however, the mechanism by which flow controls EC gene expression is not 
yet fully understood. The goal of this project was both to determine how miR-181b and 
miR-483 respond to flow, cause altered gene expression, and regulate CAVD development 
as well as to develop an accelerated in vivo model of CAVD. 
 Overall Hypothesis 
 Our overall hypothesis is that disturbed flow conditions, such as the one 
endogenously observed in the fibrosa, controls expression of genes and miRNAs that play 
a role in endothelial dysfunction, a critical early stage of CAVD. Specifically, we are 
interested in studying the role of two novel shear-sensitive miRNAs: miR-181b and miR-
483. MiR-181b is a pro-CAVD miRNA upregulated in OS conditions that targets TIMP3. 
Silencing of TIMP3 upregulates MMP activity and leads to increased ECM degradation. 
MiR-483 is a protective miRNA upregulated in LS conditions that inhibits inflammation 
and EndMT by silencing the E2 ubiquitin ligase UBE2C and the HIF1α pathway. 
 Current animal models for CAVD are unable to accurately recreate the CAVD 
pathology found in human patients (sclerosis and leaflet calcification). Furthermore, in 
order to allow researchers to better understand CAVD and to provide a fast and accurate 
system to test new therapeutics, there is a need for an accelerated animal model. Our 
approach takes advantage of a congenital valve disease known as bicuspid AV, a well-
known risk factor for CAVD that induces AV calcification at much earlier ages than 
patients with tricuspid AVs [30, 308]. To this end, we will be using GATA5 knockout mice 
which have been shown to develop bicuspid AV (~15% of the mice) [211] and inducing 
hypercholesterolemia via injection of an AAV gain-of-function PCSK9 complemented 
with high-fat diet. Our preliminary data showed that mice with bicuspid AVs present 
increased AV velocity, sclerosis, and calcification in just four months. 
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 Specific Aim I: Demonstrate the mechanosensitivity of miR-181b in HAVECs 
and its role in ECM remodeling 
 We discovered miR-181b in our previous microRNA array comparing endothelial-
enriched RNA from each side of healthy porcine AVs [220]. miR-181b was found to be 
upregulated in the fibrosa compared to the ventricularis. In this aim, we validated that miR-
181b is upregulated by OS in HAVECs.  We then proceeded to identify shear-sensitive 
targets of miR-181b by conducting an in silico analysis comparing shear-sensitive targets 
in our HAVEC array to computationally predicted targets of miR-181b. We identified 
GATA6, SIRT1, and TIMP3 from our initial validation studies and decided to focus on 
TIMP3 because it is a gene known to inhibit MMP activity and ECM degradation, a key 
step in AV sclerosis. Our functional studies showed the OS-induced MMP activity in 
valvular endothelial cells is miR-181b-dependent via silencing of TIMP3. Furthermore, 
silencing miR-181b in OS conditions leads to significant decrease in MMP activity in AV 
endothelium. 
 Specific Aim II: Determine the shear-sensitivity of miR-483, its targets and 
their function in endothelial dysfunction and AV calcification 
 We discovered miR-483 from our HAVEC array [14], where miR-483 was 
significantly upregulated in LS conditions compared to OS conditions. Furthermore, we 
harvested endothelial-enriched RNAs from each side of healthy porcine AVs and found 
that miR-483 is upregulated in the ventricularis layer (endogenously exposed to LS) 
compared to the fibrosa (endogenously exposed to OS). Our functional studies showed that 
miR-483 regulates inflammation, EndMT, and proliferation in HAVECs. To discover the 
target genes responsible for miR-483 endothelial function, we conducted an in silico 
analysis and found two shear-sensitive target genes of miR-483: ASH2L and UBE2C. 
Interestingly, knockdown of UBE2C alone dramatically prevented OS-induced endothelial 
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inflammation, demonstrating its dominant role. Although both UBE2C and ASH2L are 
likely to play major roles in CAVD, they are involved in potentially two very complex and 
different pathways (UBE2C on ubiquitin-dependent pathways and ASH2L on epigenetic 
regulation through histone modifications), and studying both simultaneously would 
interfere with focused studies; therefore, we decided to concentrate on UBE2C. 
 We discovered that UBE2C binds to pVHL, a E3 ligase that ubiquitinates and 
degrades HIF1α, leading to its degradation which in turn stabilizes HIF1α and allows 
transcription of its targets. This silencing of pVHL regulates inflammation and EndMT. To 
test whether miR-483 or HIF1α could be potential therapeutics for CAVD, we conducted 
ex vivo studies in porcine AVs in osteogenic media and treated the tissues with a miR-483 
mimic or a HIF1α inhibitor (PX478). We found that both treatments significantly decreased 
calcification.  
 Specific Aim III:  Develop an accelerated in vivo animal model for CAVD 
 As discussed in the introduction (chapter 1.6.2), several models of CAVD 
currently exist  [13, 192, 200, 309-311]. However, these models have been unable to 
present significant degrees of sclerosis and calcification in the leaflet area of AVs [200, 
312]. This lack of a fast and reliable animal model for AV calcification in the leaflets and 
not just in the root is slowing down mechanistic and therapeutic studies of CAVD. To 
address this issue, we decided to look into the main risk factors of CAVD and found that 
bicuspid AV is known to accelerate development of CAVD [44, 308]. Therefore, we 
decided to create a novel mouse model of CAVD using  GATA5-/- mice (provided by Dr. 
Mona Nemer [211]) that have been shown to develop BAVs in 15 % of the cohort versus 
littermate-control mice with tricuspid AVs. In order to accelerate the development of 
CAVD, we injected these mice with AAV-PCSK9 (which degrades hepatic LDL receptor) 
to induce hypercholesterolemia [307]. Our preliminary results showed that the BAV mice 
can develop AV sclerosis (histomorphometry), stenosis (transaortic velocity by 
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echocardiography), and calcification (Osteosense 680). These studies showed promising 
results but require further studies to demonstrate how well does this model mimic human 




 Cell Culture and Shear Experiments  
3.1.1 HAVECs 
Side-specific Human Aortic Valve Endothelial Cells (HAVECs) [from the fibrosa 
endothelium (fHAVECs) and ventricularis endothelium (vHAVECs)] were isolated from 
noncalcified AVs obtained from heart transplant surgeries (n = 6) (according to an 
Institutional Review Board-approved protocol at Emory University and Georgia Institute 
of Technology) using a brief collagenase digestion and gentle scraping method [14]. 
Confluent cells were sorted for endothelial purity in the following manner: fHAVECs and 
vHAVECs were incubated in 5 μl of DiI-acetylated LDL (acLDL; BTI) per 1 ml of 
complete media for 4 h before cell sorting using FACS Aria I (BD Biosciences). Human 
Aortic Endothelial Cells (HAECs) and human umbilical vein ECs (HUVECs) purchased 
from Lonza were used as positive controls. Human aortic SMCs (HASMCs) were used as 
a negative control. 
Cells were cultured in 100 mm dishes (Falcon 353003) coated with 0.1% gelatin 
(Sigma Aldrich G9391) for 1 hr at 37°C. Cells were used at Passages 5-7 for experiments.  
The media composition is MCDB131 (MediaTech) supplemented with 0.002µg/ml FGF, 
0.010µg/ml EGF, 0.001µg/ml VEGF, 0.002µg/ml IGF, 50µg/ml ascorbic acid, 
0.001mg/ml hydrocortisone, 1% ECGS, 10%FBS, 1% L- glutamine, and 1% penicillin-
streptomycin. 
3.1.2 Human embryonic kidney cells 293 (HEK) 
HEK cells were purchased from ATCC and cultured in gelatin coated plates with 




 Shear Stress experiments 
3.2.1 Cone and Plate Viscometer 
Briefly, cells were cultured to 100% confluency and then subjected to shear stress 
in our cone-and-plate viscometer for 24 Hr. Cells subjected to LS experienced a 
unidirectional shear stress of 15 dyn/cm2, whereas cells subjected to OS experienced an 
oscillating shear stress of 5 dyn/cm2 at 1Hz. Alignment of ECs under LS was visually 
confirmed by microscopy. Cells were scraped in 600 µL HBSS (Corning 45000-462) and 
pelleted by centrifugation at 5000 rpm for 1 minute. One third was resuspended with Qiazol 
(Qiagen 79306) and the rest was resuspended in phosphate-buffered RIPA with glycerol 
(Boston Bioproducts BP-421) and protease inhibitor (Sigma Aldrich 11697498001).  
 
Figure 3.1 LS aligns endothelial cells 
3.2.2 Ibidi shear stress experiments 
 Shear stress was applied to confluent HAVECs using an Ibidi pump system (Ibidi, 
Munich, Germany). Cells (3.3 × 105) were loaded onto μ-slides I0.4 (Ibidi) and placed in an 
incubator at 37°C with 5.0% CO2. Slide surfaces were treated with 0.1% gelatin prior to 
cell loading to improve cell adhesion. These μ-slides hold a volume of 100 μL, with a 
channel height of 400 μm and a cell culture surface area of 2.5 cm2 (5 mm width × 50 mm 
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length). We loaded HAVECS onto μ-slides overnight before induction of shear to ensure 
optimal adhesion and prevent cells from lifting off.  
 The Ibidi pump system was set up per the company's instructions and proprietary 
software was used to control the level of shear applied to cells by controlling total media 
flow rate through the channels of known dimensions. We used the red type perfusion tubing 
set that connects to the μ-slide and can induce shear stress of 4-40 dyn/cm2. Sterile filters 
(Syringe Filter  PES .22um Sterile 50, 0.22-μm pore size, EMD millipore) were used to 
filter the air entering the tubing system, via an air pressure pump, which applied the force 
required to maintain the flow rate of the media through the tubing and across the μ-slide. 
The air pressure pump responds to the company's proprietary software and provides air to 
the perfusion sets at the designated pressure with a range of −100 mbar to +100 mbar. The 
air pumped into the system came from the incubator itself and thus contained 5% CO2. 
Our initial studies show that after 3 days cells show alignment to LS conditions (Figure 
3.2B) and the cobble-like cell shape characteristic of OS conditions (Figure 3.2C). 
 
Figure 3.2 Ibidi shear system aligns HAVEC in LS conditions 
 Quantitative real-time PCR (qPCR) for validation of miRNAs 
 Total RNA was purified by the Qiagen miRNeasy Kit (217004), and reverse-
transcribed into cDNA using the Qiagen miScript II Reverse Transcriptase Kit (218161).  
The resulting cDNA was subjected to qPCR using the Qiagen mature hsa-miR-181b-5p 
(MIMAT0000257: 5'AACAUUCAUUGCUGUCGGUGGGU-3’ MS00006699), mature 
has-miR-483-3p (MIMAT0002173: 5'UCACUCCUCUCCUCCCGUCUU-3 
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MS00009751) or RNU6b (218193) as the forward primer and Universal Primer (218193) 
as the reverse primer, SYBR Master Mix (ThermoFisher 4472903), and the ABI StepOne 
Plus qPCR machine. The PCR conditions were 95°C, 15 min, followed by 45 cycles of 
94°C, 15 s; 55°C, 30 s, and 70°C, 30 s. RNU6B was used as a housekeeping control. Fold 
changes between samples were determined for all targets using the ΔΔCt method [313].  
 Quantitative real-time PCR (qPCR) for validation of mRNAs 
Total RNA was purified using the Qiagen miREasy kit and reverse transcribed for 
use in a two-step qRT-PCR using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems 4368814). The resulting cDNA was subjected to qPCR using the 
primers in Table 3.1 (human) and Table 3.2 (pig), SYBR Master Mix (ThermoFisher 
4472903), and the ABI StepOne Plus qPCR machine. The PCR conditions were 10 min at 
95°C, followed by 40 cycles of 95°C for 5 s and 60°C  for 30 s. 18S was used as a 
housekeeping control. Fold changes between samples were determined for all targets using 





Table 3.1 Primer sequences for qPCR for human samples 
 
Forward Reverse 
18S(human/pig) AGGAATTGACGGAAGGGCACCA  GTGCAGCCCCGGACATCTAAG 
VCAM1 
(human) CATTGACTTGCAGCACCACA AGATGTGGTCCCCTCATTCG 
ICAM1 
(human) CACAAGCCACGCCTCCCTGAACCTA TGTGGGCCTTTGTGTTTTGATGCTA 
MCP-1 
(human) GCAGAAGTGGGTTCAGGATT TGGGTTGTGGAGTGAGTGTT 
IL-1β (human) CCACAGACCTTCCAGGAGAATG GTGCAGTTCAGTGATCGTACAGG 
IL-6 (human) AGACAGCCACTCACCTCTTCAG TTCTGCCAGTGCCTCTTTGCTG 
UBE2C 
(human) CTGGCGATAAAGGGATTTCTGCC GCGAGAGCTTATACCTCAGGTC 
ASH2L 
(human) TTCCTGGAGACCTCTACAGAGC CCTTCTCTCAACCACAGTCAG 
PSAT1 
(human) ACTTCCTGTCCAAGCCAGTGGA CTGCACCTTGTATTCCAGGACC 
pVHL (human) GACACACGATGGGCTTCTGGTT ACAACCTGGAGGCATCGCTCTT 
HIF1α (human) TATGAGCCAGAAGAACTTTTAGGC CACCTCTTTTGGCAAGCATCCTG 
Twist1 (human) CGGACAAGCTGAGCAAGAT CTGGAGGACCTGGTAGAGGA 
Snail (human) TGCAGGACTCTAATGGAGAGTT GACAGAGTCCCAGATGAGCA 
Slug (human) CTGGCCAAACACAAGCAG ACCCAGGCTCACATATTCCT 
Transgelin 





Table 3.2 Primer sequences for qPCR for pig samples 
 
Forward Reverse 
18S(human/pig) AGGAATTGACGGAAGGGCACCA  GTGCAGCCCCGGACATCTAAG 
UBE2C (pig) ACAGTGAAGTTCCTCACGCC ATGTTGGGTTCTCCGAGCAG 
ASH2L (pig) CTTTCCGGCCATCTCACTGT GCCTCCCATCCACTTCTGTC 
KLF2(pig) GACCACGATCCTCCTTGACG GCATCAAGCCTCGATCCTCT 
VCAM1(pig) ACCAGCTCCACAGATTTCCTG TCCCTGGGAGCAACTTGAAC 
Runx2(pig) GCCTTCAAGCCATCACCTCAA GAGAACGCTGGCGATACCC 
 RNA Extraction from organs and qPCR 
 Mice were sacrificed using CO2 and the liver, lung, kidney, and spleen was 
collected from each animal. The organs were snap-frozen in liquid nitrogen and crushed 
by mortar and pestle in liquid nitrogen. After crushing, an aliquot of the tissue was placed 
in Qiazol and disrupted by metal beads in a tissue lyser (BioSpec 11079132SS). Total RNA 
was purified and reverse-transcribed as previously described.  The resulting cDNA was 
subjected to qPCR as previously described.  
 Transfection of Nucleic Acids 
 For miRNA modulation studies we plated HAVECs for 24 hours prior to 
transfection with either anti-miR-483 (Exiqon LNA Power Inhibitor 4100225-001) or anti-
miR-181b (Life technologies 4464084) for inhibition or miR-483 mimic (Exiqon 472350-
001) or miR-181b mimic (Life Technologies 4464066) for overexpression respectively. 1 
part of oligonucleotide/Oligofectamine (Invitrogen 12252011) mixture in Opti-MEM 
media (Gibco 31985070) were added to 4 parts of OPTIMEM in the plate for final dosages 
of 100 nM for anti-miR or 5-10 nM miR-mimic. Four hours after transfection, the media 
was replaced with standard HAVEC media. A non-target “scrambled” miRIDIAN 
microRNA Mimic Negative Control (Dharmacon CN-001000-01-05) was used as a control 
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in mimic experiments and a nontarget LNA oligonucleotide (Custom-made from Exiqon) 
was used as a control in anti-miR experiments.  
 We used the same protocol to transfect siRNAs to silence the expression of target 
genes. We used siRNAs to silence UBE2C (SMARTpool, Dharmacon L-004693-00-0005), 
ASH2L (SMARTpool, Dharmacon L-019831-00-0005), KLF2 (Thermo Scientific 
AM16708), pVHL (ON-TARGETplus, Dharmacon L-003936-00-0005) and HIF1α (EZN-
2968, Exiqon). The concentration of each siRNA was determined with a dose curve study 
in HAVECs where cells were treated with different concentrations of siRNA for 48 hours 
and expression of the target gene was measured via qPCR. 
 Plasmids were transfected using Lipofectamine 3000 (ThermoFisher Scientific 
L3000008) using Opti-MEM media (Gibco 31985070). GFP or RFP plasmid was used in 
order to determine transfection efficiency.  Briefly, the plasmids were mixed in serum-free 
medium with Lipofectamine 3000 and P3000 and added to the cells. After four hours, 
media was changed to regular medium. The plasmids were: pSELECT-GFP-hLC3 
(Invitrogen psetz-gfplc3), pCMV6-UBE2C Myc-DDK-tagged (Origene technologies, 
RC208741), RpCMV-DsRed-Express2 (RFP, SnapGene pIRES2 DsRed-Express 2),  pRc-
CMV-HA-pVHL-WT, HA-pVHL-RRR, HA-pVHL-KRR, HA-pVHL-RKR or HA-
pVHL-RRK [314, 315].  
 PX478 treatment  
 PX478 is an FDA-approved chemical inhibitor of HIF1α by inhibiting 
transcription, translation and stability of HIF1α [300, 301]. PX478 was purchased from 
MedKoo Scientific (MedKoo 202350-1g) and diluted in sterile saline at a concentration of 
20mM. Cells or tissues were treated with a concentration of 20μM of PX478. 
 Gelatinase assay 
 In order to determine the activity of MMPs in HAVECs, we used the EnzChek 
Gelatinase/Collagenase Assay kit (Thermo Fisher). The kit utilizes a gelatin substrate from 
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porcine skin, labeled with fluorescein, which can be degraded by gelatinases and 
collagenases such as MMPs. The level of substrate degradation is reflected by fluorescent 
signal, absorption 495 nm/emission 515 nm, read via Biotek plate reader. We incubated 
100 ul HAVEC lysate suspended in kit buffer with 20 μg DQ gelatin substrate for 2 hours, 
and then recorded fluorescent signal for each sample. Values were adjusted by subtracting 
fluorescent signal of blank wells, and normalizing to total sample protein content.   
 In vitro MMP inhibition 
 We analyzed the specific contribution of MMPs to the gelatinase fluorescence using 
MMP chemical inhibitor GM6001 (Millipore), which efficiently inhibits many MMPs, 
including MMP-1, 2, 3, 8, and 9. The cell lysate was collected, and gelatinase assay was 
performed as described above.  
 Monocyte Adhesion Assay 
 Following shear, cells were washed and incubated with fluorescently labeled THP-
1 human peripheral blood mononuclear leukocytes (ATCC TIB-202) in serum-free media 
at 37°C for 30 minutes. THP-1 cells were labeled with 5 µL of BCECF-AM (1mg/ml, 
Molecular Probes  B1150) at 37°C for 30 minutes. 500,000 THP-1 cells were added per 
dish in a volume of 5 mL. Non-adherent THP-1 cells were be washed away with and bound 
cells were fixed with 4% paraformaldehyde (Sigma Aldrich) and visualized by fluorescent 
microscopy at 5X magnification (Olympus) and quantified using ImageJ. 
 Protein assay and Western Blotting for Inflammatory Markers 
 Cell lysate was centrifuged at 12,000g for 10 minutes at 4°C to remove cell debris. 
The protein-containing supernatant was collected in a separate tube and 2.5 µL was added 
to a 96 well plate. Bicinchoninic acid (BCA) was diluted 1:50 in Reagent A (Pierce 23225) 
and 97.5 µL of the reagent was added to each protein-containing well. Protein standards 
were prepared by diluting bovine serum albumin (2mg/mL, Pierce 23209). After a 30-
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minute incubation at 37°C, the absorbance was read by a microplate reader at 562 nm and 
a linear calibration curve was established. 
 Each protein sample was diluted in 1X RIPA and 6X reducing loading dye (Boston 
Bioproducts) to achieve a total protein amount of 15-25 µg, then subsequently boiled at 
95°C for 5 minutes. Proteins were electrophoresed in 1X running buffer (Tris-Glycine pH 
8.8) using a 8-12% polyacrylamide gel. Following electrophoresis, the proteins were 
transferred to a polyvinylidene fluoride (PVDF) membrane (BioRad) and blocked in 5% 
(w/v) nonfat milk in Tris-Buffered Saline with 0.1% Tween (TBST) for 1 hour at room 
temperature. Membranes were incubated with the primary antibody solution overnight at 
4°C. Following primary antibody exposure, the membrane was washed and incubated with 
secondary antibody (1:3000) (goat anti-rabbit, goat anti-mouse or goat anti-rat HRP, Santa 
Cruz SC-2004, SC-2005 or Thermo Fisher Scientific 31470) for 1 hour at room 
temperature. After washing, the membrane was developed using Immobilon Western 
Chemiluminescent HRP (EMD Millipore, WBKLS0500) and Blue Lite Autorad Film 
(VWR, 490001-950). 
Table 3.3 List of Antibodies used for Western blotting and Immunostaining 
Antibody Species Cat. No. Company 
UBE2C (Ubch10) Rabbit Ab12290 Abcam 
ASH2L Rabbit A300-108A Bethyl Laboratories 
pVHL Rabbit SAB4200434 Sigma Aldrich 
HIF1α Rabbit A300-286A Bethyl Laboratories 
GAPDH Rabbit sc-25778 Santa Cruz Technologies 
Β-Actin Mouse A5316 Sigma Aldrich 
Myc-tag Mouse 2276S Cell Signaling Technologies 
HA-tag Rat 11867423001 Sigma Aldrich 
KI-67 Rabbit Ab15580 Abcam 
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 pVHL and HIF1α staining in shear stress conditions 
 Cells were seeded in IBIDI slides (Corning) coated in 0.1% gelatin at a density of 
50,000 cells per slide. 24 hours later, cells were transfected with siUBE2C or left untreated. 
24 hours after transfection, cells were sheared for 72 hours either in LS or OS conditions. 
After shear, cells were rapidly fixed in 4% paraformaldehyde and permeabilized in 0.1% 
Triton X-100 (Sigma Aldrich) in PBS for 10 minutes, followed by blocking in 20% goat 
serum (Jackson ImmunoResearch, 005-000-121) in PBS for 1 hour. After blocking, cells 
were incubated with pVHL or HIF1α (1:100) antibodies (see Table 3.3) overnight at 4°C 
followed by incubation with secondary antibody (1:250) (Alexa Fluor 568 conjugated goat 
anti-rabbit, Life Technologies) and imaged using a fluorescent microscope. 
 In silico analysis 
 We conducted an in silico analysis to determine potential shear-sensitive targets of 
our miRNAs. We used our previously published HAVEC array [14] to discover shear-
sensitive genes in HAVECs, we used genes with at least a 50% difference in expression 
(p<0.05) between LS and OS conditions. We compared these genes with predicted target 
genes of either miR-181b or miR-483 using online miRNA-gene interactions from 
miRtarbase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php) and miRwalk 
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk/). 
 3’UTR Luciferase assay 
 First, we transfected HAVECs with a 3’UTR luciferase plasmid containing the 
3’UTR of human TIMP3 with the binding site for miR-181b containing firefly and renilla 
luciferase. 24 hours after plasmid transfection, we transfected miR-181b mimic and 24 
hours later measured changes in expression of luciferase. We used a non-targeting miRNA 
mimic control as an experimental control. We collected the cells and measured expression 
of firefly and renilla luciferase and normalized to protein content. 
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  Scratch migration assay 
 Cell monolayers were scratched with a 200-μL pipette tip. The monolayer was 
washed once and the medium was replaced with Optimem reduced-serum (2%FBS) media. 
After 6 hours, the number of cells migrated into the scratch area were quantified 
microscopically using NIH ImageJ. 
 Tunel assay for apoptosis quantification 
 Detection of cell apoptosis was performed by using the In Situ Cell Death Detection 
Kit; Fluorescein TUNEL kit (Roche Diagnostics, Mannheim, Germany). Cells were fixed 
with 4% paraformaldehyde in DPBS (pH 7.4) for 20 min, washed with HBSS for 30 min, 
permeabilized with 0.1% Triton X-100 and 0.1% sodium citrate in HBSS (2 min on ice), 
and rinsed twice with HBSS. Staining was performed by incubating tissue sections for 1 h 
at 37°C in a humidified chamber in the dark in 50 µl of TUNEL reaction mixture. DAPI 
counterstaining was used to improve image contrast. Positive apoptotic cells could be 
identified by using the green fluorescence on the microscope. Negative controls were 
prepared by incubating fixed and permeabilized tissue sections in 50 µl of TUNEL label 
solution (without terminal transferase). Positive controls were prepared by incubating fixed 
and permeabilized tissue sections with DNase for 10 min prior to labeling. 
 Immunofluorescence Staining 
 Frozen sections were permeabilized in 0.1% Triton-X in PBS for 10 minutes, 
followed by blocking in either 20% donkey serum or goat serum (Jackson 
ImmunoResearch,005-000-121 or 017-000-121) in PBS for 1 hour. Slides were incubated 
in the primary antibody detailed in Table 3.3 overnight at 4°C followed by incubation with 
secondary antibody (1:250 v/v) (Alexa Fluor 568 conjugated goat anti-rabbit, goat anti-rat, 
or donkey anti-goat, Life Technologies). Slides were then mounted using DAPI-mounting 
media (Sigma Aldrich F6057) and imaged using a fluorescent microscope. 
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 Mouse De-paraffinization and Immunostaining 
 Briefly, sections were deparaffinized using the following protocol: 
1. Xylene: two 3-minute dips. 
2. 1:1 Xylene:100% ethanol: 3-minute dip. 
3. 100% ethanol: 3-minute dip. 
4. 95% ethanol: 3-minute dip. 
5. 70% ethanol: 3-minute dip. 
6. 50% ethanol: 3-minute dip. 
7. Water: keep in water until staining. 
 Following de-paraffinization, slides were stained with hematoxylin and eosin or 
Alizarin red, or immunostained as described below. 
 Hematoxylin and Eosin Staining 
 Frozen sections or paraffin-embedded sections were stained using the American 
MasterTech H&E kit. The protocol is the following: 
1. Rinse in running tap water for two minutes 
2. Incubation in Harris hematoxylin for five minutes 
3. Rinse in running tap water for two minutes 
4. Incubation in differentiating solution for one minute 
5. Rinse in running tap water for two minutes 
6. Incubation in Bluing solution for thirty seconds 
7. Rinse in 70% ethanol for one minute 
8. Incubation in Eosin for one minute 
9. Dehydration via three changes of 100% ethanol  
10. Incubation in 100% xylene for one minute 
11. Mount in Permount 
12. Image using Hammamatsu Nanozoomer 
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 Alizarin red staining 
 Frozen sections or paraffin-embedded sections were stained using 2% Alizarin Red 
Stain (Lifeline Cell Technology CM-0058). Briefly, sections were fixed with 4% 
paraformaldehyde for 15 minutes followed by two washed with PBS. Slides were stained 
in the alizarin red solution for 90 seconds followed by two washes with DI water. 
 Statistical Analysis 
 Statistical analyses were carried out with Graph-Pad Prism v6 (GraphPad 
Software). All error bars reported are standard error of the mean unless otherwise indicated. 
Pairwise comparisons were performed using one-way Student’s t-tests. Multiple 
comparisons of means were performed using one-way analysis of variance followed by 
Tukey’s multiple comparison tests. Differences between groups were considered 




4 Role of miR-181b in extracellular matrix remodeling in CAVD 
 Introduction 
 The sclerosis and calcification of the aortic valve is a side-specific phenomenon, 
correlated with the differential shear stresses observed during the cardiac cycle. Each side 
of the valve experiences a distinct shear profile sensed by the overlying endothelium. The 
ventricularis layer faces the ventricle and experiences a high-magnitude and pulsatile, 
unidirectional, laminar shear stress (LS) and rarely calcifies. The fibrosa layer facing the 
aorta experiences low magnitude and oscillatory shear stress (OS). This endothelial layer 
exhibits a highly inflammatory phenotype, expressing abundant adhesion molecules and 
other inflammatory markers, and downregulating anti-inflammatory signals such as Klf2. 
The fibrosa preferentially exhibits sclerosis and calcification, with large nodules and 
macrophage infiltration mimicking atherosclerosis observed in the spongiosa and 
interstitium near this valve face. In vitro, LS conditions applied to aortic valve endothelial 
cells upregulate CAVD-protective genes such as KLF2, KLF4 and eNOS, whereas OS 
conditions upregulate pro-CAVD genes and paracrine mediators such as BMP4, 
Cathepsin-K, and matrix metalloproteinases MMP-2 and MMP-9 [14, 316].  
 Notably, the matrix metalloproteinases (MMPs) have been correlated with valve 
disease in various studies of human and porcine valves. MMP levels are known to be higher 
at sites of calcification in both the endothelium and the interstitial cells. However, the 
mechanism by which MMPs are upregulated in CAVD conditions has not yet been 
discerned, and while their causative role in cancers and atherosclerosis has been shown, 
their contribution to CAVD remains undefined [257, 258, 317] . MMPs are known to 
degrade extracellular matrix (ECM) to allow for cellular growth, migration, or infiltration 
as observed in tumor metastasis. The remodeling of the ECM has been previously studied 
in the context of aortic valve stenosis and calcification [259-262], but the activity of MMPs 
in that phenomenon are still unknown. In addition, the potentially important mechanism by 
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which low and oscillatory shear-stress may mediate MMP activity and extracellular matrix 
degradation in CAVD have not been previously characterized. 
 In order to find novel pathways regulating CAVD in the aortic valve, our group has 
recently performed a microarray exploring side- and shear-dependent RNA expression in 
aortic valve endothelium [318]. We isolated endothelial enriched RNA from fresh porcine 
valves to determine which RNA is uniquely expressed on each side of the valve. In 
addition, we subjected human aortic valve endothelial cells (HAVECs) to LS or OS for 24 
hours to determine mechanosensitive RNA expression. Our array revealed many side- and 
shear-dependent microRNAs (miRNAs). miRNAs are short (18-22) nucleotide sequences 
which bind to the 3’-untranslated regions (3’UTR) of mRNA thereby regulating protein 
expression by degradation of mRNA targets or by suppression of translation [319]. Despite 
their characterization in other cardiovascular systems, miRNAs have not been thoroughly 
explored in the AV endothelium. In the interstitium, these mediators have proven to be 
critical for regulation of osteogenic transformation: miRNA-30b was shown to prevent  
interstitial cells transforming into calcifying cells [320], and miRNA-141 targets TGF-β 
and BMP-2 signaling, which are critical for valvular interstitial osteoblastic differentiation 
leading to tissue calcification[226]. From our array analyses, we discovered one 
microRNA, miR-181b, that is abundant in HAVECs and consistently upregulated in OS in 
vitro. This microRNA was also predicted to regulate the previously undefined 
TIMP3/MMP pathway, and thus was chosen as a potential novel therapeutic candidate for 
further study.  
 MiRNA-181b has been shown to be shear-sensitive in aortic valve endothelial cells 
[14] as well as side-specific in porcine aortic valves [220] however, its potential role in 
CAVD has yet to be discovered. In order to determine the mechanistic role of miR-181b 
in HAVECs, we conducted an in silico analysis to determine its predicted and partially 
validated target genes. From this analysis we found that miRNA-181b targets TIMP3, a 
known inhibitor of MMPs that has been previously shown to be shear-sensitive and critical 
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in preventing matrix remodeling in atherosclerosis [263]. Via overexpression and 
inhibition of miR-181b along with TIMP3 3’UTR luciferase reporter studies, we found that 
TIMP3 is a direct target of miR-181b. Through a series of gelatinase assays showing 
HAVEC MMP activity, we found that miR-181b suppresses TIMP3 in OS conditions 
leading to increased ECM degradation and remodeling (Fig. 4.1). These findings provide 
a novel therapeutic target for CAVD by targeting miR-181b or TIMP3 to prevent ECM 




Figure 4.1 miR-181b induces endothelial ECM degradation by targeting TIMP3 
High-magnitude laminar shear stress at the ventricularis suppresses endothelial expression 
of miR-181b, leading to an increase in TIMP3 expression. TIMP3 inhibits MMP activation 
and extracellular matrix degradation, protecting the ventricularis from further events 
leading to valve calcification. Low-magnitude oscillatory shear stress at the fibrosa 
stimulates endothelial expression of miR-181b, which downregulates TIMP3, leading to 
increased MMP activity and extracellular matrix degradation. This remodeling of the ECM 





4.2.1 miR-181b is side-specific and shear-sensitive in valvular endothelium 
 miR-181b was found to be side-specific in our microarray where it was upregulated 
by two-fold in the fibrosa (exposed to OS) compared to the ventricularis (exposed to LS) 
in porcine valvular endothelium (Fig. 4.2A). Interestingly, miR-181b was also shear-
sensitive in our HAVEC microRNA array where we observed a significant 15% increase 
in miR-181b expression in OS compared to LS conditions (Fig. 4.2B). To validate the 
shear-sensitivity of this miRNA we exposed HAVECs to LS or OS conditions for 24 hours 
and measured miRNA expression of three miRNAs in the miR-181 family (miR-181a, -
181b, and -181c) as well as miR-15a, a control miRNA known not to be shear-sensitive 
(Fig. 4.2C). Our results showed that only miR-181b was shear-sensitive being upregulated 
by more than six-fold in OS compared to LS conditions in HAVECs. 
4.2.2 TIMP3 is a potential shear-sensitive target of miR-181b 
 To identify potential shear-sensitive targets of miR-181 we conducted an in silico 
analysis using predicted targets of miR-181b from miRTarBase 
Figure 4.2  miR-181b is side-specific and shear-sensitive in valvular endothelium 
A) Expression of miR-181b in the ventricularis (V) and fibrosa (F) layer of porcine valvular 
endothelium from our microarray. B)  Expression of miR-181b in HAVECs exposed to LS 
or OS conditions for 24 hours from our microarray. C) HAVECs were exposed to LS or 
OS conditions for 24 hours and expression of miR-181a, -181b,-181c, and -15a was 
quantified via qPCR normalized to U6. n=4-8, *p<0.05. 
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(http://mirtarbase.mbc.nctu.edu.tw/) and miRwalk (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2/) comparing to genes that are downregulated in OS 
conditions from our previously published HAVEC array [14]. From this study we identified 
six target genes: NLK, GATA6, CDX2, TIMP3, VSNL1, BCL2 and SIRT1.  We probed 
for these genes in sheared HAVECs in LS or OS conditions for 24h, and we found that 
GATA6, TIMP3 and SIRT1 were highly shear-sensitive, showing a significant decrease in 
OS compared to LS conditions (Fig. 4.3A). Because of its known role in matrix degradation 
and our group’s previous work in studying TIMP3 in atherosclerosis [263], we focused on 
TIMP3 for further study. To further validate its shear-sensitivity we harvested endothelial-
enriched RNAs from each layer of healthy porcine AVs and measure mRNA expression of 
TIMP3 via qPCR and found that there was a ~35% decrease of TIMP3 expression in the 
fibrosa compared to the ventricularis (Fig. 4.3B) 
 TIMP3 is an inhibitor of extracellular matrix degradation through MMP inhibition 
that potentially links previous studies describing increased ECM degradation in stenotic or 
calcific valves compared to healthy valves [258, 317] . As a functional readout of matrix 
remodeling in HAVECs, we conducted a  gelatinase assay using DQ gelatin [321], which 
Figure 4.3 TIMP3 is shear-sensitive in HAVECs 
A) HAVECs were exposed to LS or OS conditions for 24 hours and mRNA expression of 
the potential predicted targets of miR-181b was assessed via qPCR. B) Endothelial-
enriched RNAs were harvested from each side of porcine AVs and expression of TIMP3 
was assessed via qPCR. n=4-6, *p<0.05. 
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has been shown to correlate with MMP activity and matrix degradation [318] . Correlating 
with the loss of TIMP3 in OS, we observed a 2.5-fold increase in gelatinase activity in 
HAVECs sheared in OS compared to LS conditions (Fig. 4.4). Our hypothesis is that the 
miR-181b/TIMP3 pathway is a critical mediator of the OS-induced MMP activity observed 
in HAVECs.  
  
Figure 4.4 OS induces MMP activity in HAVECs 






4.2.3 miR-181b regulates TIMP3 expression 
Next, we want to determine whether miR-181b regulates expression of TIMP3. 
First of all, we conducted a dose curve to find the optimal miR-181b dose by treating 
HAVECs with miR-181b mimic or mimic-control for 48 hours and measured expression 
of miR-181b via qPCR (Fig. 4.5A). We found that there was a dose-dependent increase in 
miR-181b expression when treating HAVECs with a miR-181b mimic and from our results 
we decided to use 5nM as it increased miR-181b expression by ~1000 fold compared to 
the control mimic. We then treated HAVECs with miR-181b or mimic control at 5nM for 
48 hours and measured mRNA expression of all the target genes identified in our in silico 
analysis via qPCR (Fig. 4.5B). GATA6, TIMP3 and SIRT1 expression was consistently 
downregulated when miR-181b was overexpressed. 
Figure 4.5 miR-181b upregulation decreases GATA6, TIMP3 and SIRT1 expression 
A) HAVECs were transfected with different doses of miR-181b mimic for 48 hours and 
expression of miR-181b was quantified via qPCR. B) HAVECs were transfected with miR-
181b mimic or control at 5nM for 48 hours and expression of potential target genes of 




 Next, we conducted a similar experiment but instead of overexpressing miR-181b 
we silenced its expression by using a miR-181b inhibitor (anti-181b). We treated HAVECs 
with anti-181b or anti-miR control at a dose of 100nM and measured expression of miR-
181b (Fig. 4.6A) or its potential target genes (Fig. 4.6B) via qPCR. We observed that 
GATA6, TIMP3 and SIRT1 were upregulated when miR-181b was silenced. Even though 
we observed consistent results with these three genes we will be focusing on TIMP3 due 
to our previous experience with TIMP3 and its role in ECM degradation, critical step in 
CAVD pathogenesis [263]. 
 Last, to further validate that miR-181b directly binds to the 3’UTR of TIMP3 we 
designed a plasmid with the 3’UTR sequence of TIMP3 where miR-181b potentially binds 
to TIMP3 tagged to a firefly luciferase protein. We treated transfected HAVECs with this 
plasmid and 24 hours later we conducted a second transfection with miR-181b mimic. 
After 24 hours we measured firefly luciferase signal and normalized to protein content in 
each sample (Fig. 4.7). Our results showed that there was a dose-dependent decrease in 
Figure 4.6 MiR-181b inhibition upregulates GATA6, TIMP3 and SIRT1 
A,B) HAVECs were transfected with anti-Control (Control) or anti-miR-181b for 48 hours 
and expression of miR-181b (A) or potential target genes of miR-181b (B) was quantified 
via qPCR. n=4,*p<0.05. 
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luciferase signal which demonstrated that miR-181b directly binds to the 3’UTR of TIMP3 
regulating its expression. 
4.2.4 miR-181b regulates ECM degradation via silencing of TIMP3 
We found that miR-181b regulates TIMP3, an inhibitor of tissue 
metalloproteinases, therefore, we hypothesize that miR-181b regulates ECM degradation 
via silencing of TIMP3. To this end, we studied whether miR-181b regulates ECM 
degradation in HAVECs by upregulating miR-181b (via miR-181b mimic) or silencing 
miR-181b (via anti-miR-181b) in HAVECs for 48 hours and measuring MMP activity (Fig. 
4.8) via DQ gelatin assay.  We found that upregulation of miR-181b lead to increased 




Figure 4.7 MiR-181b directly binds to the 3’UTR of TIMP3 
HAVECs were co-transfected with a luciferase plasmid containing the 3’UTR TIMP3 
sequence where miR-181b binds and miR-181b mimic or control. After 48 hours luciferase 
expression was quantified and normalized to protein content. n=4, *p<0.05 
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 We then proceeded to determine if the effect of miR-181b in MMP activity was 
TIMP3-dependent. First, we treated HAVECs with anti-miR-181b and siRNA targeting 
TIMP3 (siTIMP3) for 48 hours and measured MMP activity via DQ gelatin assay (Fig. 
4.9A). Our results showed that 1) silencing of TIMP3 increases gelatinase activity and 2) 
the decrease of gelatinase activity that we observed when silencing miR-181b can be 
prevented by silencing TIMP3.  Second, we treated HAVECs with miR-181b mimic and 
GM6001 (MMP inhibitor) at 30nM for 48 hours and measured MMP activity via DQ 
gelatin assay (Fig. 4.9B). From this study we found that 1) use of MMP inhibitor decreased 
gelatinase activity in HAVECs and 2) the increase in gelatinase activity that occurred when 
miR-181b was upregulated can be reverted by using an MMP inhibitor such as GM6001. 
These results showed that miR-181b regulates ECM degradation by silencing TIMP3 
which increases MMP activity.  
 
  
Figure 4.8 MiR-181b regulates ECM degradation in HAVECs 
A,B) HAVECs were transfected miR-181b mimic (A), anti-miR-181b (B), or  its 





4.2.5 miR-181b regulates shear -regulated ECM degradation in HAVECs 
To test whether OS-induced MMP activity is controlled by mechanosensitive miR-
181b, we subjected HAVECs treated with miR-181b mimic to either LS or OS conditions 
for 24h. First, we quantified the levels of miR-181b after shear was applied and we found 
that miR-181b levels were increased dramatically in both LS and OS after miR-181b 
treatment (Fig. 4.10A), and this increase in miR-181b expression correlated with increased 
gelatinase/MMP activity in both shear stress conditions (Fig. 4.10B). Notably, the usually 
low levels of gelatinase activity observed in LS were increased 4-fold after treatment with 
miR-181b mimic. We performed the same studies using HAVECs treated with anti-miR-
181b under LS and OS. Anti-miR-181b treatment decreased miR-181b by 80% (Fig. 
4.10C), and the normally high levels of MMP activity observed in OS were abrogated upon 
anti-miR-181b treatment (Fig. 4.10D). These data suggest that the shear-dependent change 
in matrix degradation we observed in HAVECs is dependent on miR-181b, which may be 
a master miRNA regulator of shear-dependent matrix changes in the aortic valve 
endothelium. 
Figure 4.9 miR-181b regulates ECM degradation by silencing TIMP3 
A) HAVECs were co-transfected with anti-miR-181b, siTIMP3, or its respective controls 
for 48 hours and gelatinase activity was assayed via DQ gelatin assay. B) HAVECs were 
transfected with miR-181b mimic and treated with GM6001 (MMP inhibitor) at 30nM for 




 Discussion and future directions 
These studies are the first to show a direct effect of mechanosensitive miRNAs on 
matrix degradation in the aortic valve endothelium. While the levels and activity of MMPs 
have been suggested in previous studies to play a role in the degradation of the valvular 
extracellular matrix contributing to calcification [261, 322, 323], this work suggests a 
causative endothelial mechanosensitive pathway responsible for this phenomenon. MMPs 
Figure 4.10 miR-181b is responsible for shear-dependent ECM degradation 
A-B) HAVECs were transfected with miR-181 mimic (181b mimic) or mimic control 
at 5nM for 24h before application of 24h shear-stress conditions either LS or OS. 
Expression of mir-181b was quantified via qPCR (A), and MMP activity was 
measured via gelatinase activity assay (B). C-D) HAVECs were transfected with anti-
miR-181b (anti-181b) or anti-miR control at 100nM for 24h previous to application 
of either LS or OS. Expression of mir-181b was quantified via qPCR (C) and MMP 
activity was measured via gelatinase activity assay (D). n=4, *p<0.05. 
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are critical for the progression of cardiovascular disease, including atherosclerosis [324-
326] and ischemia reperfusion injury [327, 328]. However, MMP activity has not been 
shown to participate directly in valve calcification, and MMP-mediated ECM degradation 
may participate in the progression of inflammatory cell infiltration [260, 329]. Here, we 
have highlighted a novel pathway, showing TIMP3 inhibition of MMP activity is vital for 
maintenance of valve endothelial cell homeostasis, and disturbed flow leads to 
downregulation of TIMP3 via mechanosensitive microRNA-181b. This increases MMP 
activity and leads to increased matrix degradation, known to lead to worsened valve 
sclerosis and calcification [21, 330].  
 While TIMP3 has previously been identified as a major regulator of matrix 
remodeling [331], our current work is the first to identify its role in the valve endothelium. 
In separate studies, our group has shown that TIMP3 is downregulated by disturbed flow 
in atherosclerosis via miR-712, which leads to exacerbated MMP activity and lesion 
formation [318]. The study highlighted here shows a similar role for TIMP3 in the valvular 
endothelium, although under the control of a different mechanosensitive microRNA, miR-
181b. We have performed a microarray to determine microRNAs that are 
mechanosensitive in HAVECs and porcine valves [220], which proved a powerful tool in 
determining microRNAs which may be regulated by differential flow in the valve. The 
array revealed miR-181b to be significantly upregulated in disturbed flow and the porcine 
fibrosa, which was confirmed by qPCR shown in these studies..  
 The targeting of TIMP3 by microRNA-181b has been described in the context of 
cancers, including gastric cancer [305] and hepatocellular carcinoma [332]. In these 
diseases, miR-181b suppresses TIMP3 and increases MMP activity, allowing for tumor 
growth and infiltration into the surrounding tissue environment. These studies correlate 
with our observations that miR-181b downregulates TIMP3 in the valve endothelium, 
which increases matrix remodeling, critical for valve sclerosis and calcification. The 
analysis of this pathway in previous studies may also point toward a regulatory pathway 
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upstream: Wang et al. found that miR-181b can be induced by alteration of transforming 
growth factor-beta and its Smad targets [332]. This pathway and its relevance to the aortic 
valve warrant further study in the valve endothelium and is a focus of our future work.   
 Our current studies demonstrate the pathological role of microRNA-181b induced 
by disturbed flow in valve endothelium. Our work clearly shows that mechanosensitive 
microRNA-181b targets and downregulates TIMP3 via binding to the TIMP3 3’UTR, 
leading to increased MMP-mediated degradation of extracellular matrix. This microRNA 
in particular has been studied at length in various endothelial cells and diseases [303, 304, 
333, 334]. It seems to play a conflicting role in disease progression or protection depending 
on tissue and disease context. In elegant and thorough studies, microRNA-181b was shown 
to protect against atherosclerosis by inhibiting endothelial inflammation [303]. Circulating 
miR-181b was found to be reduced in the blood of patients with coronary artery disease 
and ApoE-/- mice fed with high-fat diet also presented lower levels of miR-181b in the 
aortic intima layer. Systemic delivery of miR-181b in ApoE-/- fed with high-fat diet 
inhibited atherosclerotic lesion formation, proinflammatory gene expression and the influx 
of lesional macrophages and CD4+ T cells in the vessel wall. While our current work shows 
an opposing role for this microRNA in the valve, this incongruity may indicate a complex 
system of regulation of microRNA-181b that is context-dependent. In certain cancers, miR-
181b is tumorigenic [335], while it may regulate glucose levels in adipose tissue [334]. 
Thus, our work combined with the previously defined pathways of miR-181b regulation 
indicate a tissue-specific role for this microRNA. While more work is required to determine 
the reasons for the differences observed between our studies and others, we have clearly 
observed a pathological role for miR-181b in the valve endothelium.  
 We have also shown here that microRNA-181b targets other genes in HAVECs, 
including SIRT1 and GATA6. These studies are the first to demonstrate the 
mechanosensitivity of both of these genes, and their targeting by microRNA181b. In fact, 
the role of SIRT1 and GATA6 in the valve has not yet been described. Thus, these represent 
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novel targets for future studies. Both of these genes are known to play a protective role in 
atherosclerosis: in an angiotensin-induced model of atherosclerosis, SIRT1 induces 
endothelial relaxation and may inhibit the formation of foam cells in the vasculature [336]. 
GATA6 protects against intimal hyperplasia by controlling smooth muscle cell 
differentiation as well as inhibiting VCAM-1 expression in treated endothelial cells [337]. 
Both of these targets present novel avenues of study in the aortic valve, and prove to be as 
important as TIMP3 in maintaining valvular homeostasis and tissue integrity. When taken 
together, the wide array of functions controlled by target genes of miR-181b suggest that 
this miRNA may be a master regulator of aortic valve endothelial cells under disturbed 
flow, orchestrating a complex a multi-faceted change in the phenotype of the cells and the 
structure of the whole valve. The pathway we have highlighted in this Aim may be just one 
of many important for this change, and thus further analysis is necessary to obtain a better 
overall picture of miR-181b network regulation.  
 
A substantial portion of this chapter was published in: 
Fernandez Esmerats J.*, Heath JM*, Khambounenheuang L., Kumar S. Jo H., 
“Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix 





5 Role of miR-483 in HAVEC biology and AV calcification 
 Introduction 
 In this Aim, we focus on studying the role the novel shear-sensitive miRNA from 
our HAVEC array, miR-483. Recently, miR-483 has been shown to target the connective 
tissue growth factor (CTGF), which mediates EndMT in human umbilical vein ECs [273]. 
In another study using vascular smooth muscle cells and heart cells, treatment with 
angiotensin II reduced expression of miR-483, which was shown to target four members 
of the renin-angiotensin system: AGT, ACE-1, ACE-2 and AGTR2 [271]; however, the 
role of miR-483 in HAVEC biology and CAVD is still unknown. Our initial studies 
validated our array results showing that miR-483 is shear-sensitive in vitro in sheared 
HAVECs as well as in porcine AVs where we found that miR-483 is expressed in a side-
dependent manner in the valvular endothelium. 
 Here, we found that UBE2C is a major target of miR-483 [338]. UBE2C, also 
known as UBCH10, is an E2 ubiquitin conjugating enzyme. While overexpression of 
UBE2C is well documented in various cancer tissues and cells [277, 290, 292, 294, 339], 
its role in endothelial function and cardiovascular disease is yet to be determined. 
Ubiquitination is upregulated in calcified valves [340], but its underlying mechanisms and 
whether it plays any role in AV calcification or endothelial function is unknown. 
Interestingly, Hypoxia-Inducible Factor 1-α (HIF1α) expression, which is controlled by 
Von Hippel Lindau protein (pVHL) [284, 285, 341, 342], is upregulated by d-flow 
conditions in vascular ECs and atherosclerotic conditions [343]. UBE2C is a member of 
the Anaphase Promoting Complex/Cyclosome (APC/C), which is also known to bind to 
pVHL [279]. Therefore, we hypothesize that UBE2C regulates the HIF1α pathway by post-
transcriptionally regulating pVHL via ubiquitination. 
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 In this Aim, we show the novel mechanism by which the miR-483 target, UBE2C, 
regulates the pVHL and HIF1α pathway, leading to endothelial inflammation, EndMT, and 
subsequent AV calcification. We also show evidence suggesting that miR-483 mimic and 
HIF1α inhibitors may serve as potential therapeutics to prevent and treat CAVD. 
 Results 
5.2.1 miR-483 is side-specific and shear-sensitive in valvular endothelium 
 miR-483 was found to be shear-sensitive in our microRNA array where we found 
that LS upregulated its expression compared to OS conditions [14]. Here, we validated the 
shear-sensitivity of miR-483 by exposing HAVECs to LS or OS conditions for 24 hours 
and measuring expression of miR-483 via qPCR (Fig. 5.1A). We found that there was a 
~70% decrease of miR-483 expression in OS compared to LS conditions.  Next, we wanted 
to study whether miR-483 was expressed in a side-specific manner in aortic valves. We 
harvested healthy porcine aortic valve leaflets and isolated endothelial-enriched total 
RNAs from each side of the valve and measured expression of miR-483 via qPCR (Fig. 
5.2B) where we found that there was a ~two-fold increase in miR-483 expression in the 
ventricularis (endogenously exposed to LS) compared to the fibrosa (endogenously 
exposed to OS). These studies validated our previous array data and showed that miR-483 
is also a side-specific miRNA in the aortic valve which further reinforces our hypothesis 




5.2.2 miR-483 regulates inflammation, EndMT, proliferation and apoptosis in HAVECs 
 Once we validated the shear- and side-sensitivity of miR-483 we proceeded to 
determine the functional role of miR-483 in valvular endothelium. To this end we have 
studied the following functions: inflammation, EndMT, proliferation, apoptosis and 
migration. To study the role of miR-483 we treated cells with a miR-483 mimic at a dose 
of 10nM (to overexpress miR-483), an anti-miR-483 at a dose of 100nM (to inhibit 
expression of miR-483) or its respective controls. After treating HAVECs with miR-483 
mimic or anti-miR-483 for 48 hours, we collected the cells and measured expression of 
miR-483 via qPCR and found that treatment with the miR-483 mimic increased expression 
of miR-483 by ~280-fold while treatment with anti-miR-483 silenced miR-483 by ~75% 




Figure 5.1 Regulation of miR-483 in HAVECs 
HAVECs were treated with 10nM of miR-483 mimic or 100nM of anti-miR-





The first endothelial function that we studied was inflammation. We have assessed 
inflammation by conducting a monocyte adhesion assay, and by measuring inflammation 
markers. HAVECs were treated with miR-483 mimic or anti-miR-483 in static conditions 
for 48 hours and monocyte adhesion assay (Fig. 5.3A) or measurement of inflammation 
markers via qPCR (Fig. 5.3B) was performed. Our results showed that increased levels of 
Figure 5.2 Regulation of miR-483 in HAVECs 
HAVECs were treated with 10nM of miR-483 mimic or 100nM of anti-miR-483 
(or  controls) for 24 h and expression of miR-483 was assessed via qPCR. n=4, 
*p<0.05 
Figure 5.3 miR-483 regulates inflammation in static HAVECs 
A,B) Inflammation studies were conducted in HAVECs by treating with a miR-483 mimic 
(483-mimic) or control (Mimic-Ctrl) or a miR-483 inhibitor (Anti-483) or control (Anti-
Ctrl). Monocyte adhesion assay was conducted (A) as well as quantifying the 
inflammation markers IL-6, ICAM-1, VCAM-1 or KLF2 (B). n=6-10, *p<0.05.   
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miR-483 lead to a decrease in monocyte adhesion and a decrease in pro-inflammatory 
markers such as IL-6, VCAM1 and ICAM1 while silencing of miR-483 induced 
endothelial inflammation.   
 To determine the functional role of miR-483 in shear-induced endothelial 
inflammation we treated HAVECs with miR-483 mimic or anti-miR-483 for 24 hours and 
exposed the cells to OS or LS conditions respectively for 24 hours. Monocyte adhesion 
(Fig. 5.4A) and inflammation marker quantification (Fig. 5.4B and 5.4C) was conducted. 
We found similar results as in static conditions, increased levels of miR-483 decreased OS-
induced inflammation while silencing of miR-483 lead to increased inflammation in LS-
Figure 5.4 miR-483 regulates shear-induced inflammation in HAVECs 
A-C) Inflammation studies were conducted in HAVECs by treating with a miR-483 
mimic (483-mimic) or control (Mimic-Ctrl) and applying OS shear stress conditions 
or a miR-483 inhibitor (Anti-483) or control (Anti-Ctrl) and applying LS shear 
stress conditions. Monocyte adhesion assay was conducted (A) as well as 
quantification of the inflammatory markers IL-6, ICAM-1, VCAM-1 or KLF2 (B, 
C). n=6-10, *p<0.05. 
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conditions. These results showed that miR-483 plays a role in static as well as shear-
induced inflammation in HAVECs. 
 Next, we studied the role of miR-483 in EndMT as it is a cellular process well-
known to be involved in the pathogenesis of CAVD [344]. To this end, we treated HAVECs 
with miR-483 mimic in static conditions for 48 hours and measured expression of EndMT 
markers via qPCR (Fig. 5.5A). From this study we observed that miR-483 did not affect 
EndMT in static conditions. Knowing that EndMT is highly regulated by shear stress we 
decided to treat HAVECs with miR-483 mimic or anti-mir-483 for 24 hours and then 
expose the cells to OS or LS conditions for 24 hours respectively. We then quantified 
expression of EndMT markers in shear conditions (Fig. 5.5B and 5.5C) via qPCR. These 
studies showed that treatment with miR-483 mimic in OS conditions leads to a significant 
decrease in Twist1, Snail and Transgelin while treatment with anti-miR-483 in LS 
conditions leads to increased levels of Twist1, Snail, Transgelin and Slug. These results 
Figure 5.5 miR-483 regulates shear-induced EndMT 
A) HAVCs were treated with miR-483 mimic for 48 hours and expression 
of EndMT markers was quantified via qPCR. B,C) HAVECs were 
transfected with miR-483 mimic or anti-miR-483 for 24 hours and exposded 
to OS or LS shear conditions for 24 hours respectively. Expression of 
EndMT markers was quantified via qPCR.n=4, *p<0.05. 
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showed that miR-483 controls shear-induced EndMT in HAVECs and that treatment with 
miR-483 mimic leads to decreased EndMT in disturbed flow conditions 
 We have also studied proliferation, apoptosis and cell migration by treating 
HAVECs with miR-483 mimic or anti-miR-483 for 48 hours and then conducting 
functional studies for each of the different cellular functions. To measure proliferation, we 
fixed the treated HAVECs and stained with KI-67, a well-known marker of 
proliferation[345], and quantified percentage of cells that were positive for this marker 
(Fig. 5.6A). We found that treatment with miR-483 mimic lead to decreased proliferation 
while silencing of miR-483 via anti-miR-483 treatment lead to increased proliferation. 
Next, we studied apoptosis by conducting a TUNEL assay and quantifying percentage of 
apoptotic cells (Fig. 5.6B). We observed that anti-miR-483 lead to increased apoptosis 
while treatment with miR-483 mimic had no effect on apoptosis. Last, we measured cell 
Figure 5.6 miR-483 regulates proliferation and apoptosis but has no effect in 
cell migration.  
A) Proliferation (via KI-67 staining), B) apoptosis (via TUNEL staining), and C) 
migration (via scratch assay) were assessed in HAVECs treated with miR-483 
mimic or anti-miR-483. n=3-6, *p<0.05 
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migration by conducting a scratch assay and measuring the average speed of the scratch 
closure (Fig. 5.6C) and found that miR-483 had no effect on HAVEC migration. 
 Overall, our data suggests that miR-483 plays a role in HAVEC inflammation, 
EndMT, proliferation and apoptosis. These functions are known to be involved in CAVD 
and therefore it reinforces our hypothesis that miR-483 plays a protective role in the 
ventricularis side. However, we will focus on studying inflammation and EndMT as there 
are the most critical functions relevant to CAVD. 
5.2.3 KLF2 regulates expression of IGF2 and miR-483 
 miR-483 is located in the intronic region of the Insulin-like growth factor 2 (IGF2) 
between exons 7 and 8 (Fig. 5.7A). Interestingly, KLF2, a well-known shear-sensitive gene 
in the endothelium [5, 306], was found to upregulate expression of IGF2 in a study 
conducted by Dekker et al [346]. Therefore, we hypothesize that KLF2 will drive the 
expression of IGF2 and miR-483 (Fig. 5.7A). We first measured the expression of KLF2, 
IGF2 and miR-483 by qPCR in HAVECs exposed to LS or OS for 24 hours (Fig. 5.7B) 
and found that these three genes were significantly upregulated in LS compared to OS 
Figure 5.7 miR-483 is an intronic miRNA in IGF2 regulated by KLF2 
A) Genomic location of miR-483 in the IGF2 gene. B) HAVECs were exposed to LS or 
OS shear stress conditions for 24 hours and expression of KLF2, IGF2 and miR-483 was 
quantified via qPCR. C) HAVECs were treated with siKLF2 for 24 hours and expression 
of KLF2, IGF2 and miR-483 was quantified via qPCR. n=4, *p<0.05. 
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conditions. We then treated HAVECs with siKLF2 at 50nM for 48 hours and quantified 
the expression of KLF2, IGF2 and miR-483 by qPCR (Fig. 5.7C) and found that decrease 
of KLF2 leads to decreased levels of IGF2 and miR-483 thus suggesting that KLF2 
regulates IGF2 and miR-483 expression in HAVECs. It has been previously shown that 
KLF4 regulates expression of miR-483 in the endothelium [273] but this is the first time it 
has been shown that the shear-sensitive KLF2 regulates miR-483 expression. 
 
5.2.4 miR-483 regulates shear-dependent expression of UBE2C and ASH2L 
 To determine the mechanisms by which miR-483 exerts its function in valvular 
endothelium we identified shear-sensitive targets regulated by miR-483. To this end, we 
conducted an in silico analysis comparing predicted targets of miR-483 (950 predicted 
genes by the miRWalk and miRTarBase databases) with OS-induced genes (239 genes) 
from our previous HAVEC transcriptome array study (Fig. 5.8A) [14]. This in silico 
Figure 5.8 In silico analysis to identify potential shear-sensitive targets of miR-
483 
A,B) An in silico analysis was conducted by comparing predicted targets of miR-483 
(from miRwalk and mirtarbase databases) with OS-induced genes in HAVECs from our 
previously published array 9, resulting in 9 potential shear-sensitive target genes (A). 
The shear-sensitivity of these 9 genes was validated by qPCR in HAVECs exposed to 
LS or OS conditions for 24h (B). n=4,*p<0.05 
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analysis revealed nine genes that were predicted gene targets of miR-483 and shear-
sensitive genes in our HAVEC transcriptome microarray: ABCB9, ASH2L, DHX33, 
GADD45B, PSAT1, PSEN2, TMEM88, TOMM20, and UBE2C (Fig. 5.8B). To validate 
their shear-sensitivity, HAVECs were exposed to LS or OS conditions for 24 hours and the 
expression of these nine genes was measured by qPCR. This study indicated that just six 
of these nine genes were increased by OS compared to LS conditions in HAVECs (Fig. 
5.9B).   
 We next determined which of these six shear-sensitive genes were regulated by 
miR-483 using the miR-483-mimic or anti-miR-483. The results showed that ASH2L, 
UBE2C and PSAT1 were consistently downregulated when HAVECs were treated with a 
miR-483 mimic (Fig. 5.9A) and they were upregulated when HAVECs were treated with 
anti-miR-483 (Fig. 5.9B) while the other three genes did not respond to changes to miR-
483 expression in HAVECs. 
 We further validated if the shear-sensitive expression of ASH2L, UBE2C and 
PSAT1 were mediated by miR-483 by treating HAVECs with miR-483 mimic or anti-miR-
Figure 5.9 ASH2L, UBE2C and PSAT1 are regulated by miR-483 in static HAVECs 
A,B) HAVECs were treated with miR-483-mimic or anti-miR-483 for 48 hours. Expression 
of predicted targets of miR-483 was assessed in cells treated with miR-483 mimic (A) or 
anti-miR-483 (B) by qPCR. n=4, *p<0.05.   
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483 for 24 hours followed by OS or LS for 24 hours. Cell lysate was collected and 
expression of ASH2L, UBE2C and PSAT1 was measured by qPCR Our results showed 
that shear-dependent expression of ASH2L and UBE2C was controlled by miR-483 in 
HAVECs while PSAT1 was not (Fig. 5.10A and 5.10B). We then determined if UBE2C 
and ASH2L were also shear-sensitive as the protein level by exposing HAVECs to LS or 
OS conditions and measuring protein expression of UBE2C and ASH2L by western blot. 
At the protein level, OS exposure significantly increased ASH2L and UBE2C expression 
compared to the LS condition in HAVECs (Fig. 5.10C and 5.10D).  
 ASH2L is a histone methyltransferase responsible for the trimethylation of histone 
3 lysine 4 (H3K4me3). This epigenetic modification induces chromatin opening allowing 
for gene transcription [347]. H3K4me3 has been shown to be upregulated in lymphatic 
endothelial cells [348] as well as in aortic valve stenosis where it was shown to be 
upregulated in the promoter region of pro-osteogenic genes in a Notch1+/- mouse model of 
AV stenosis [349]. UBE2C is an E2 ligase in the ubiquitin pathway that interacts with the 
Figure 5.10 UBE2C and ASH2L are shear-sensitive targets of miR-483 in HAVECs 
A,B) The three top predicted shear-sensitive targets of miR-483 (Ash2L, UBE2C and PSAT1) 
were validated by treating HAVECs with either a 483-mimic or an anti-miR-483 in OS 
conditions (A) or LS conditions (B) respectively. C,D) Shear-sensitivity of Ash2L and UBE2C 
at the protein level was quantified in HAVECs exposed to LS or OS shear stress conditions. 
GAPDH protein levels were quantified as loading control. D) Quantification of western blot 
bands using ImageJ.  n=3-4, *p<0.05 
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Anaphase promoting complex (APC/C) [350]. Interestingly, ubiquitination has been shown 
to be upregulated in calcified human AVs [340] thus making UBE2C a more interesting 
target for further study and the main focus of this thesis Aim. UBE2C has been previously 
shown to be regulated by miR-483 via 3’UTR luciferase assay [338] and to further validate 
that miR-483 regulates its expression in HAVECs we treated HAVECs with miR-483 for 
24 hours followed by 24 hours of OS. Cells were collected, and western blotting was 
conducted to measure protein levels of UBE2C (Fig. 5.11A). We found that miR-483 
decreased OS-induced levels of UBE2C. Last, we stained sclerotic human valves and 
stained for UBE2C (Fig. 5.11C) and found that UBE2C was significantly upregulated in 
the fibrosa layer compared to ventricularis (Fig 5.11D). These results demonstrated that 
UBE2C is regulated in vivo by the endogenous shear stress conditions and that it may play 
a role in the development of side-specific CAVD. 
5.2.5 miR-483 exerts its anti-inflammatory role via silencing of UBE2C 
 As we have previously shown, miR-483 reduced valvular endothelial inflammation 
(Fig. 5.3 and 5.4). To determine whether UBE2C played a role in the anti-inflammatory 
role of miR-483 we transfected HAVECs with anti-miR-483 or siUBE2C alone or co-
transfected with anti-miR-483 and siUBE2C and measured inflammation via monocyte 
Figure 5.11 UBE2C is side-specific and is regulated by miR-483 in OS conditions 
A,B) HAVECs were treated with miR-483 mimic for 24 hours followed by OS for 24 hours. 
Protein expression of UBE2C was measured by western blotting (A) and quantified via 
ImageJ (B) . C,D) Non-calcified human AVs were stained with UBE2C antibodies and with 
DAPI (C). Quantification was conducted via ImageJ (D). n=3-5,*p<0.05. 
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adhesion (Fig. 5.12A) and quantified the pro-inflammatory markers VCAM1 and ICAM1 
(Fig. 5.12B). We found that silencing of UBE2C decreased inflammation while silencing 
of anti-miR-483 increased inflammation. Interestingly, when we silence both UBE2C and 
miR-483 we observed inflammation levels similar to our control conditions showing that 
the pro-inflammatory effect of anti-miR-483 can be prevented by silencing UBE2C. To 
further validate the pro-inflammatory role of UBE2C, HAVECs were transfected with a 
UBE2C overexpression plasmid (1μg and 2.5µg), and we conducted a monocyte adhesion 
assay (Fig. 5.12C). This study showed a UBE2C-dose-dependent increase in monocyte 
adhesion.   
5.2.6 UBE2C mediates OS-induced endothelial inflammation and EndMT 
 Next, we tested if OS-induced pro-inflammatory and pro-EndMT endothelial 
responses could be reverted by knockdown of UBE2C in HAVECs by treatment with 
siUbe2c. UBE2C knockdown prevented OS-induced monocyte adhesion and induction of 
the pro-inflammatory markers (VCAM1 and ICAM1) without affecting KLF2 or ASH2L 
Figure 5.12 UBE2C regulates miR-483 dependent anti-inflammatory effect in 
HAVECs 
A,B) HAVECs were co- transfected with siUBE2C or siCtrl and anti-miR-483 (AM-483) 
or anti-miR-control (AM-Ctrl), followed by monocyte adhesion (A) and qPCR analysis for 
inflammatory markers (B). C) HAVECs transfected with UBE2C overexpression plasmid 
or GFP plasmid were used for monocyte adhesion assay. n=6-10, *p<0.05. 
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expression in HAVECs (Fig. 5.13A and B).  Moreover, siUBE2C treatment significantly 
reduced several markers of EndMT (TWIST1, TAGLN and SLUG) (Fig. 5.13C). Together, 
these results showed that UBE2C is indeed a key miR-483 target gene, which plays a 
dominant role in OS-induced pro-inflammatory and pro-EndMT responses in HAVECs. 
5.2.7 pVHL and HIF1α are shear-sensitive in HAVECs and are regulated by UBE2C 
 We hypothesized that the increase in UBE2C (due to the loss of miR-483 under the 
OS condition) leads to ubiquitination and degradation of pVHL, which in turn increases 
HIF1α levels, leading to increased expression of its target genes, endothelial inflammation 
and EndMT (Fig. 5.14A). First, we found that the expressions of pVHL and HIF1α were 
highly shear-sensitive, but inversely regulated in HAVECs. Under LS exposure for 72 
hours in the Ibidi® shear system, expression of pVHL was high, while HIF1α expression 
was undetectable. In contrast, under OS, pVHL was low while HIF1α was high at the 
protein and mRNA levels (Fig. 5.14B-D). 
  
Figure 5.13 UBE2C regulates OS-induced endothelial inflammation and EndMT 
A-C) HAVECs treated with siUBE2C or siRNA control (SiCtrl) for 24 hours, followed 
by OS or LS conditions for another 24 hours. Then, monocyte adhesion (A) and qPCR 
analyses for markers of inflammation (B) and EndMT (C) were carried out normalized 
to 18S.  n=6-10, *p<0.05. 
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 Next, we studied whether the shear-sensitivity observed in pVHL and HIF1α was 
regulated in a UBE2C-dependent manner. To this end, we treated HAVECs with siUBE2C 
and applied LS or OS conditions and measured protein levels of pVHL and HIF1α. We 
found that UBE2C silencing significantly increased pVHL expression while preventing 
HIF1α induction under the OS condition (Fig. 5.15 A-D), demonstrating that UBE2C 
regulates shear-dependent expression of pVHL and HIF1α. 
 
  
Figure 5.14 pVHL and HIF1α are shear-sensitive in HAVECs 
A) Depicts a hypothesis that overexpression of UBE2C ubiquitinates pVHL, leading to 
increased HIF1α level, endothelial inflammation and EndMT. B-D) HAVECs sheared for 
72 hours by LS or OS were immunostained with antibodies for pVHL or HIF1α (B) and 




Next, we tested whether the shear-dependent expression of UBE2C, pVHL, and 
HIF1α observed in HAVECs in vitro was consistent in vivo using immunohistochemical 
staining on human AVs. UBE2C and HIF1α expression was significantly higher in the 
fibrosa-side of the human AV leaflets, whereas pVHL expression was higher in the 
ventricularis-side (Fig. 5.16A and B). Furthermore, markers of inflammation (VCAM1), 
EndMT (TWIST1), and calcification (RUNX2) (Fig. 5.16A and B) were highly expressed 
in the fibrosa side demonstrating side-dependent expression of pro-CAVD markers. These 
staining results clearly corroborate the side-dependent expression of UBE2C, pVHL, and 
HIF1α, with markers of inflammation, EndMT, and calcification in the fibrosa side of 
human AVs.  
 
  
Figure 5.15 UBE2C mediates shear-dependent expression of pVHL and HIF1α 
A) HAVECs treated with siCtrl or siUBE2C for 24 hours, followed by exposure to OS for 
24 hours were analyzed by Western blot (A) and ImageJ quantification (B) for pVHL. For 
HIF1α study, HAVECs exposed to OS for 72 hour were immunostained with the HIF1α 
(C) and Image J quantified (D). n=4-6. *p<0.05 
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5.2.8 UBE2C binds and ubiquitinates pVHL, leading to its degradation. 
 We next examined how UBE2C (a E2 ubiquitin ligase) regulates pVHL expression. 
Although UBE2C is a member of APC/C, which is known to bind and ubiquitinate pVHL 
for proteasomal degradation [279], it was unknown whether UBE2C can mediate pVHL 
ubiquitination.  Therefore, we tested whether UBE2C mediates pVHL expression in a 
ubiquitination-dependent manner. To this end, HAVECs were transfected with siUBE2C, 
and ubiquitinated proteins were immunoprecipitated and western blotted using a pVHL 
antibody. We found that knockdown of UBE2C decreased ubiquitinated pVHL levels in 
the immunoprecipitates (Fig. 5.17A). This result was independently validated by 
immunoprecipitating pVHL first, followed by ubiquitin western blotting, demonstrating 
that ubiquitination of pVHL was reduced when UBE2C was knocked down in HAVECs 
(Fig. 5.17B). As expected, levels of pVHL in these cell lysates were increased when 
Figure 5.16 UBE2C, pVHL and HIF1α are expressed in a side-dependent manner 
in human AV leaflet 
A) Human AVs with sclerosis were stained with antibodies to UBE2C, pVHL, HIF1α, 
Twist1 and Runx2 with DAPI nuclear staining, and B) shows quantification of the 
fluorescent intensities of each staining in endothelial layer on each side using Image J. 
Mean+sem n=5, *p<0.05. F: fibrosa, V: ventricularis.  
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UBE2c was silenced as quantified by ImageJ and normalized to β-ACTIN (Fig. 5.17C and 
D).  
 Since UBE2C has never been shown to bind and ubiquitinate pVHL, we tested 
whether they associate with each other by co-transfecting HEK cells with plasmids 
overexpressing UBE2C or RFP as a control and HA-pVHL-WT or HA-pVHL-RRR 
mutant. The HA-pVHL-RRR mutant has its three Lys ubiquitination sites (K159, K171 
and K196) modified to Arg so that they cannot be ubiquitinated [314, 315]. We used HA-
tag antibody to immunoprecipitate HA-pVHL-WT and HA-pVHL-RRR. UBE2C co-
immunoprecipitated with either HA-pVHL-WT or HA-pVHL-RRR (Fig. 5.18A). 
Interestingly, the pVHL Western blot of HA-pVHL immunoprecipitates showed bands at 
~28, 34, 55, 80 kDa, potentially representing poly-ubiquitinated pVHLs in a manner 
dependent on UBE2C and pVHL-ubiquitination sites (Fig. 5.18A). Furthermore, the 
Western blot using the ubiquitin antibody for the HA-pVHL immunoprecipitates showed 
Figure 5.17 UBE2C regulates pVHL ubiquitination in HAVECs 
A-B) HAVECs transfected with siUBE2C or siCtrl were immunoprecipitated 
with an antibody for ubiquitin (Ub) (A) or pVHl (B) and Western blotted with 
the pVHL (A) or Ub (B) antibody. C-D) Cell lysate control was western blotted 
for pVHL and β-ACTIN (C) and quantified by ImageJ. n=3 *p<0.05 
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ubiquitinated proteins at ~35, 40, 85, 100 kDa in a manner dependent on UBE2C and 
pVHL-ubiquitination sites (Fig. 5.18B).  
 Next, we tested whether UBE2C regulates pVHL levels in a ubiquitination-
dependent manner by co-transfecting HEK cells with plasmids overexpressing UBE2C or 
RFP control and HA-pVHL WT or mutants. Four different HA-pVHL double or triple 
mutants on the three Lys ubiquitination sites were used (RRR, KRR, RKR, and RRK) in 
comparison to WT [314, 315]. Expression of pVHL-WT and the three pVHL double 
mutants, but not the RRR triple mutant was decreased as UBE2C expression increased in 
a dose-dependent manner (Fig. 5.19 and 5.20). This result clearly demonstrates that pVHL 
degradation is UBE2C-dependent and it requires at least one of the three Lys ubiquitination 
Figure 5.18 UBE2C binds and ubiquitinates pVHL 
A,B) HEK cells co-transfected with myc-UBE2C or RFP plasmid (1μg) and HA-pVHL-
WT or HA-pVHL-RRR mutant plasmids (0.5μg) for 48 hours were immunoprecipitated 
using the antibody to HA-tag and Western blotted with antibodies to UBE2C or pVHL 
(A) (exposed using High intensity ECL and Low intensity ECL) or to Ubiquitin (B) . 
Untreated (Unt) HEK cells were used as a control.  
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sites. These results also demonstrate that UBE2C binds to pVHL and mediates its 
degradation by the ubiquitination-dependent manner. 
Figure 5.19 Degradation of pVHL by UBE2C requires pVHL ubiquitination sites 
A-D) HEK cells co-transfected with HA-pVHL-WT or HA-pVHL-RRR mutant 
plasmids and increasing dose of UBE2C (0.5-2μg) or RFP plasmids for 48 hours were 
lysed and Western blotted with antibodies to pVHL and b-actin as an internal control 
(A,C), and ImageJ quantitated (B,D). n=3 *p<0.05. 
Figure 5.20 UBE2C degrades pVHL in a lysine-dependent manner 
A-F) HEK cells were co-transfected with UBE2C (myc-tagged UBE2C) and HA-
tagged pVHL plasmids HA-pVHL-KRR (A, B), HA-pVHL-RKR (C, D) or HA-
pVHL-RRK (E, F). Western blots for HA-tag and β-ACTIN was conducted (A, C, 
E) and pVHL was quantified using ImageJ. n=3, *p<0.05 
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5.2.9 pVHL and HIF1α mediate UBE2C-dependent inflammation and EndMT in 
HAVECs. 
 Next, we tested whether pVHL and HIF1α regulate endothelial inflammation and 
EndMT by using sipVHL or siHIF1α in HAVECs.  Knockdown of pVHL increased 
monocyte adhesion (Fig. 5.21A) as well as markers of inflammation and EndMT 
(Fig.5.21B). We also found that knockdown of pVHL did not affect HIF1α mRNA levels. 
This was expected (Fig. 5.21B) as pVHL is known to regulate HIF1α protein levels via 
ubiquitination and proteasome degradation [284, 351]. 
  
Figure 5.21 Silencing of pVHL leads to increased endothelial inflammation 
A, B) HAVECs were transfected with sipVHL for 48 hours. Treated cells were 
then used for monocyte adhesion assay (A) or qPCR analyses for markers of 
inflammation and EndMT (B) normalized to 18S. n=4. *p<0.05. 
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 In contrast, knockdown of HIF1α via siHIF1α inhibited monocyte adhesion (Fig. 
5.22A) and markers of inflammation and EndMT, while not affecting pVHL levels 
(Fig..22B). We then tested whether UBE2C-induced endothelial inflammation and EndMT 
is mediated by either pVHL or HIF1α, using siUBE2C, sipVHL or siHIF1α in combination. 
Knockdown of both, UBE2C and pVHL, induced endothelial inflammation and EndMT 
(Fig. 5.22C and D). In contrast, silencing of both, UBE2C and HIF1α, inhibited 
inflammation and EndMT (Fig. 5.22C and D). These results suggest that endothelial 
inflammation and EndMT, induced by UBE2C, is mediated by pVHL and HIF1α in 
HAVECs. 
 
Figure 5.22 pVHL and HIF1α mediate UBE2C-induced endothelial 
inflammation and EndMT. 
A, B) HAVECs were transfected either individually with siHIF1α, and SiCtrl (A, B) 
or co-transfected with sipVHL or siUBE2C (C, D) for 48 hours. Monocyte adhesion 
assay (A, C) or qPCR analyses for markers of inflammation and EndMT (B, D) 
normalized to 18S were done. n=4. *p<0.05. 
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5.2.10 MiR-483 mimic and HIF1α chemical inhibitor PX478 inhibit calcification in 
porcine aortic valves 
 Next, we tested whether the shear-dependent miR-483, UBE2C, pVHL and HIF1α 
pathway plays a significant role in CAVD. To this end, miR-483 mimic and the HIF1α 
inhibitor PX478 were selected as treatments. We cultured freshly obtained healthy porcine 
AV leaflets in osteogenic media [352] for 14 days to induce AV calcification (Fig. 5.23A). 
Treatment with the miR-483 mimic (20nM every three days) significantly inhibited AV 
calcification as measured by Alizarin Red staining (Fig. 5.23B and C) and Arsenazo assay 
Figure 5.23 The miR-483-mimic reduces AV calcification by silencing of 
Ube2c 
A) Freshly harvested porcine AV leaflets were transfected with miR-483 mimic or 
Ctrl mimic (20nM) every 3 days for two weeks in osteogenic media (OM). AV 
leaflets were then divided for total RNA isolation and qPCR assay for miR-483 (A), 
immunohistochemical assay using Alizarin Red (B, C) and antibodies for UBE2C, 
pVHL and HIF1α (E, F) and Arsenazo calcium assay (D). Alizarin images were 
quantified using Matlab (B, C) while the fluorescence images (E, F) were quantified 
by ImageJ. n=8, *p<0.05. 
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(Fig. 5.34D). The anti-calcific effect of miR-483 was mediated by decreasing UBE2C and 
HIF1α while upregulating pVHL (Fig. 5.23 E and F). 
 Additionally, we decided to study the potential therapeutic role of HIF1α inhibitors 
currently used in clinical trials for cancer treatment. To this end, we treated porcine AVs 
with PX478 (20μM replenished every three days) which showed a dramatic inhibition of 
AV calcification (Fig. 5.24 A-C) and significantly decreased HIF1α expression (Fig. 5.24 
Figure 5.24 HIF1α inhibitor PX478 reduces AV calcification 
A) Freshly harvested porcine AV leaflets were transfected with PX478 (20μM) or 
saline every 3 days for two weeks in osteogenic media (OM). AV leaflets were then 
divided for immunohistochemical assay using Alizarin Red (A,B) and antibody for 
HIF1α (D,E) and Arsenazo calcium assay (C). Alizarin images were quantified using 




D and E).  These results demonstrate the therapeutic potential of targeting miR-483 and 
the HIF1α pathway in CAVD. 
 Summary and discussion 
 The main findings of this aim are that miR-483 is a novel shear-sensitive and side-
dependent miRNA that regulates endothelial inflammation and EndMT by targeting 
UBE2C, which in turn regulates pVHL and HIF1α under normal atmospheric conditions, 
ultimately leading to AV calcification. We also found that miR-483 mimic as well as the 
HIF1α inhibitor PX478 effectively reduced AV calcification of porcine AVs ex vivo.  
 We found that miR-483 expression is increased by LS and in the ventricularis side 
which is exposed to s-flow, while decreased by OS and in the fibrosa side which is exposed 
to d-flow. Our results demonstrated that miR-483 potently regulates endothelial function 
by protecting against inflammation, proliferation, and EndMT. The role of miR-483 was 
reported mostly in cancer cells where it regulates proliferation [268, 353] and apoptosis 
[268, 269, 354]; however, the role of miR-483 is still unclear in the cardiovascular system. 
Recent data showed that miR-483 mediates EndMT by targeting CTGF in human umbilical 
vein ECs [273]. Angiotensin II was shown to inhibit expression of miR-483 targeting the 
renin-angiotensin system genes in smooth muscles and heart [271]. These genes including 
CTGF, however, were not shear sensitive in our gene array study using HAVECs and 
porcine AVs [14, 220]; therefore, we did not study them. miR-483 is located in the intronic 
region of insulin-like growth factor 2 (IGF2), and that it was shown to be mediated by 
KLF4 [273]. Similarly, we found that expression of miR-483 and IGF2 are mediated in a 
KLF2-dependent manner in HAVECs.  
 We have identified UBE2C and ASH2L as two shear-sensitive targets of miR-483 
through our in silico and validation studies. ASH2L is a member of the COMPASS 
complex responsible for histone 3 lysine 4 tri-methylation, an important epigenetic 
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modification that induces expression of numerous genes [347]. Although it is likely that 
ASH2L plays a critical role in epigenetic modification of endothelial function and CAVD, 
we decided to save this study for the future because investigating this highly complex 
pathway simultaneously with UBE2C studies would make the scope of this aim too diffuse. 
In addition, our studies showed that UBE2C alone plays a dominant role in regulation of 
inflammation and EndMT, further supporting our rationale to focus on UBE2C in this 
study.  
 UBE2C is a member of the APC/C and is known to catalyze the initial mono-
ubiquitination of protein substrates such as cyclins [355-357]. Once cyclins are mono-
ubiquitinated, another E2 ligase, Ube2s, then elongates the ubiquitin chain (poly-
ubiquitination) leading to their proteasomal degradation [358, 359]. Interestingly, pVHL is 
another well-known substrate of both APC/C [279] and Ube2s [360, 361], but it was 
unknown whether UBE2C regulates pVHL ubiquitination. Additionally, OS was shown to 
stabilize HIF1α expression under normal atmospheric conditions in vascular endothelial 
cells by activating NF-κβ and inducing expression of the deubiquitinating enzyme Cezanne 
[343];  however, it was unknown whether pVHL, a well-known HIF1α regulator [284, 285, 
341, 342], is regulated by shear stress and regulates HIF1α expression under flow 
conditions. We found that pVHL is highly shear-sensitive, losing its expression in OS in 
HAVECs and in the fibrosa side exposed to d-flow in a UBE2C-dependent manner. 
Conversely, OS increased HIF1α expression in a UBE2C-dependent manner in HAVECs 
and in the fibrosa side. These findings suggest that UBE2C regulates pVHL and HIF1α 
expression in HAVECs. Although there is an increase in HIF1α expression under OS 
condition, it is interesting to note that siRNA-mediated knockdown of UBE2C is able to 
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significantly reduce the HIF1α expression by post-translational pVHL-mediated 
degradation preventing the downstream HIF1α signaling cascade. 
 Mechanistically, we found that UBE2C targets pVHL by binding and mediating its 
degradation in a ubiquitination-dependent manner. Furthermore, our data using the pVHL 
ubiquitination site mutants indicates that binding of UBE2C to pVHL is independent of the 
ubiquitination sites on pVHL; however, the UBE2C-dependent degradation of pVHL 
requires at least one of its ubiquitination sites. The degradation of pVHL further led to 
increased stabilization of HIF1α, which in turn induced endothelial inflammation, EndMT 
and AV calcification (Fig. 5.25). 
 To our knowledge, this is the first time that UBE2C and pVHL are shown to be 
shear-sensitive and play a role in endothelial inflammation and EndMT. We also found that 
HIF1α is also shear-sensitive and is a potent pro-inflammatory and pro-EndMT protein in 
HAVECs. Using the combination of UBE2C, pVHL and HIF1α siRNAs, we found that 
pVHL and HIF1α mediate the UBE2C-dependent inflammation and EndMT.  
 Currently, the only treatment option for CAVD patients is AV replacement or repair 
and there are no effective medical therapies. Therefore, there is an urgent need for 
Figure 5.25 Working hypothesis 
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developing CAVD therapies [210].  Our study demonstrates that miR-483 and HIF1α -
pathway are potential therapeutic targets for CAVD. Treatment with the miR-483 mimic 
or the HIF1α inhibitor PX478 significantly reduced AV calcification of porcine AVs 
demonstrating their potential as novel anti-CAVD therapeutics. Notably, numerous clinical 
trials are underway using various HIF1α inhibitors for cancer treatments [2, 362, 363]. Our 
study with PX478 demonstrates the potential of repurposing some of these FDA-approved 
HIF1α drugs to prevent and treat CAVD. Given our findings, it may be interesting to 
monitor those patients treated with HIF1α inhibitors for CAVD and atherosclerosis. 
 While our current in vitro studies focus mostly on studying the effect of shear stress 
on AV endothelial cells, it is important to note that the expression of UBE2C, pVHL, 
HIF1α and markers of inflammation, EndMT and AV calcification is regulated in a side-
dependent manner in vivo as we observed in the human AV tissues. These findings suggest 
that the miR-483-dependent UBE2C/pVHL/HIF1α pathway established based on the in 
vitro studies is relevant under in vivo conditions as well, where AVs are exposed to multiple 
mechanical forces such as pressure and stretch in addition to shear stress.     
 In conclusion, we identified a shear-sensitive and side-dependent miRNA, miR-
483, which targets UBE2C in AV endothelial cells. In turn, the aberrant expression of 
UBE2C leads to degradation of pVHL, which increases HIF1α level resulting in 
endothelial inflammation, EndMT and AV calcification. The miR-483 mimic and HIF1α 




6 Development of an accelerated animal model of CAVD using 
GATA5 mice 
 Introduction 
 Several mouse models of CAVD have been developed [13, 192, 200, 309-311]. The 
majority of these models involve various genetically engineered strains  (ApoE-/-, LDLR-
/-, Klotho-/-, Notch1+/-, eNOS-/-) with or without additional supplements, surgery, or 
physical injury to mimic various pro-CAVD conditions [192]. While most of them develop 
some features of CAVD, AV sclerosis, and stenosis; bona-fide calcification as measured 
by Alizarin red or micro-CT within the leaflets has rarely been observed [200, 312]. This 
rarity of mouse models that can easily and reproducibly develop AV leaflet calcification 
similar to humans within a reasonable time-frame (less than ~4 months), is a well-known 
roadblock that should be addressed in order to make mechanistic studies of CAVD more 
feasible. We now have developed a congenital BAV mouse model that develops a robust 
AV leaflet thickening and calcification within 4 months on a high fat-diet.  
 BAV is the most common congenital heart valve disease and is well-known to 
accelerate progression of CAVD, it is thought to have a genetic etiology due to the 
increased prevalence once one member of a family presents BAV phenotype. To better 
understand the potential genetic implications for CAVD, several genetic studies have been 
conducted comparing tricuspid AV patients with BAV patients [364-366]. From these 
studies, GATA5 was found to be associated with BAV. GATA5 is a member of the GATA 
family of transcription factors that regulate cell expansion and differentiation. Its absence 
in mice lead to increased blood pressure, endothelial dysfunction, age-dependent organ 
damage, hypertension, and BAV. Mechanistically, its loss disrupts proper endothelial 
signaling and homeostasis [367]. GATA5-/- mice (provided by Dr. Mona Nemer [211]) 
have been found to develop BAVs in 15 % cohort vs littermate-control tricuspid AV mice 
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as well as present increased AV velocity and thickened AV leaflets. Therefore, we will use 
this model combined with a gain-of-function AAV-PCSK9 (which degrades hepatic LDL 
receptors) to induce hypercholesterolemia   [307] . Our preliminary studies have shown 
that these BAV mice developed robust AV sclerosis (histomorphometry), stenosis 
(transaortic velocity by echocardiography) and calcification (Osteosense 680). 
Additionally, we showed a drug delivery method to treat AV leaflets with oligonucleotide 
as proof-of-concept for future therapeutic studies. 
 Results 
6.2.1 Injection of PCSK9 induces hypercholesterolemia in GATA5 knockout mice 
 In order to determine whether GATA5-/- knockout mice have a bicuspid or 
tricuspid AV, we conducted ultrasound echocardiography at 8 weeks of age and assessed 
aortic valve velocity using pulse-wave doppler imaging modality (Fig. 6.1). The aortic 
valve velocity for a healthy mouse is in the range between 700-1400mm/s [310]. Therefore, 
Figure 6.1 GATA5-/- mice with bicuspid AV present higher AV velocity by ultrasound 
At 2 months of age, the AV velocity of GATA5 KO mice was assessed by ultrasound in 
order to determine AV phenotype. 
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we considered our mice to have biscuspid AV phenotype whenever the AV velocity 
exceeded 1400mm/s.  
 After AV velocity was assessed and mice were separated according to AV 
phenotype, we injected the mice with an AAV-PCSK9 mutant (gain-of-function) to induce 
hypercholesterolemia supplemented with high-fat diet [307].  After PCSK9-injection mice 
were kept on high-fat diet for four months and ultrasound echocardiography was conducted 
monthly to monitor changes in AV velocity (Fig. 6.2A B). As control we had un-injected 
mice fed with high-fat diet. At the end of the study, the mice were sacrificed; and plasma 
samples were collected and sent for cholesterol quantification (Fig. 6.2C). Our studies 
Figure 6.2 GATA5-/- mice develop BAV and AV sclerosis.  
GATA5-/- mice with BAV vs tricuspid AV vs wild-type controls were used to measure 
trans-AV velocity (n=3) (B). All GATA5-/- mice were injected with AAV-PCSK9 and 




showed all PCSK9-injected mice presented increased cholesterol levels as well as increase 
in AV velocity by the end of the study. 
 
6.2.2 GATA5-/- bicuspid AV mice develop sclerosis and calcification 
 Aortic valves from GATA5-/- mice were harvested at the end of the study and 
embedded in paraffin for sectioning. H&E staining was conducted on the sectioned AVs 
(Fig. 6.3) and they were imaged using Hamamatsu Nanozoomer. From these stainings we 
found that the BAV mice had developed significant sclerosis (valve thickening) compared 
to both the tricuspid AV group or the control group. Interestingly, we observed a small 
increase in valve thickness between PCSK9-injected tricuspid AV mice and un-injected 
control mice; which would explain the increase in AV velocity observed between these 
two groups at 4 months of age (Fig. 6.2B). Furthermore, we found that both bicuspid or 
tricuspid mice had atherosclerotic plaque in the aortic sinus area compared to the control 
mice. 
 In order to assess presence of calcification, we conducted Osteosense 680 staining 
on the AV sections from the GATA5-/- mice (Fig. 6.4). We found that BAV mice showed 
Figure 6.3 . Hypercholesterolemic BAV GATA5-/- mice develop AV sclerosis  
GATA5-/-  were stained with H&E to study sclerosis (arrows).  Shown are 
representative of three mice. 
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6.2.3 Ube2c levels are increased in BAVs of GATA5 mice 
 Ube2c has previously been shown to be a critical mediator in AV calcification (Aim 
2). Therefore, we tested whether sclerotic and calcified mice AV leaflets presented higher 
levels of Ube2c compared to non-sclerotic AV leaflets. We stained BAVs and TAVs of 
Figure 6.4 Hypercholesterolemic BAV GATA5-/- mice develop AV 
calcification 
GATA5-/-  were stained with Osteosense 680 to study calcification (arrows).   
Figure 6.5 BAVs have higher Ube2c 
expression compared to TAV in 
GATA5-/- mice as shown by  
Ube2c staining was conducted on AV 
leaflets from our GATA5 study. 
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GATA5 mice with an antibody against Ube2c (Fig. 6.5); which showed that BAV leaflets 
had higher expression of Ube2c compared to non-sclerotic TAV leaflets. This suggests that 
Ube2c may play a role in the pathogenesis of AV sclerosis and calcification. 
6.2.4  SubQ injection of fluorescently labeled siRNA is delivered to the AV. 
 Having identified miR-483 as a potential therapeutic target for CAVD, we decided 
to conduct pilot drug-delivery studies with fluorescently labeled siRNA that presents a 
similar structure to miRNA mimics in mice. This was done to determine if we can deliver 
oligonucleotides to mice AV leaflets. 10-week-old wild-type mice were injected with 
1mg/kg of fluorescently labeled siRNA (Alexa-Fluor 555) or saline control subcutaneously 
(subQ). Three hours after injection, the hearts were harvested, embedded in OCT, and 
cryosectioned. We then conducted DAPI staining and imaged in a fluorescent microscope 
to determine whether our siRNA delivery was succesful. We observed that the 
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fluorescently-labeled siRNA was successfully delivered to the AV (Fig. 6.6) while control 
mice showed no signal on the AV leaflets. 
 
 Summary and discussion 
 Our results showed that we have developed an accelerated model of CAVD by 
combining two CAVD risk factors: bicuspid aortic valve, a well-known CAVD risk factor, 
and, hypercholesterolemia. Mice as young as eight weeks of age can be treated with AAV-
PCSK9 to induce hypercholesterolemia; and after four months of being fed a high-fat diet, 
a mild increase in aortic valve velocity can be observed. These BAV mice also develop 
mildsclerosis as well as microcalcifications in the leaflets. We have also demonstrated that 
Figure 6.6 SiRNA delivery to the AV by using SubQ injection.   
Ten-week-old wild-type mice were injected with siRNA-AF555 (or saline 
control) at a dose of 1mg/kg for three hours. Hearts were then sectioned and 
stained with DAPI prior to imaging in a fluorescent microscope. 
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we can target the AV by subQ injection of a fluorescently labeled siRNA giving us a tool 
to test our miRNA therapeutics in vivo. 
 We are interested in testing the therapeutics developed in Aim 2 of this model in 
order to determine whether treatment with the miR-483 mimic or the HIF1α inhibitor 
PX478 can prevent sclerosis and calcification in HAVECs. Furthermore, this accelerated 
model could be used not only to determine if our therapeutics can prevent CAVD, but also 
if they can reverse or stop progression of CAVD. To this end, we could start our in vivo 
studies and two months into the high-fat diet we could start treatment with miR-483 mimic 
or PX478 and determine if we can reverse sclerosis and calcification on these mice. 
 Additionally, we will crossbreed the GATA5-/- mice with Ube2c transgenic mice 
that overexpress Ube2c (kindly provided by Dr. Van Deursen [368]) in order to 
demonstrate whether overexpression of Ube2c in mice accelerates the pathogenesis of 
CAVD. We expect that if we treat these mice with PX478, it will prevent CAVD; thus 







 In this dissertation, we have discovered and studied two novel shear-sensitive 
miRNAs in the aortic valve endothelium: miR-181b and miR-483-3p (miR-483); and 
studied their functional role in aortic valve endothelial biology and CAVD by examining 
their respective targets (TIMP3 and UBE2C respectively) and the pathways in which they 
are involved. These miRNAs were first identified in our HAVEC and porcine AV 
microRNA array and were validated in vitro and in vivo in this dissertation. We have also 
developed a novel accelerated in vivo model for CAVD combining two well-known risk 
factors of CAVD: bicuspid aortic valve (BAV) via GATA5 knockout in mice, and 
hypercholesterolemia via AAV-PCSK9 injection. 
 MiR-181b was discovered in our side-specific porcine AV microRNA array, where 
it was shown to be upregulated in the endothelium of the fibrosa side (prone to AV 
calcification) compared to the ventricularis side (mostly spared from disease). 
Furthermore, miR-181b was found to be significantly upregulated in low-magnitude 
oscillatory shear stress conditions (OS) compared to high-magnitude unidirectional shear 
stress conditions (LS) in our HAVEC array, and was validated by qPCR in HAVECs. We 
found that in HAVECs, TIMP3, GATA6, and SIRT1 were shear-sensitive genes regulated 
in a shear-dependent manner by miR-181b. We focused on TIMP3 due to our previous 
experience with this target gene in atherosclerosis [263]. We further demonstrated that 
miR-181b directly binds to TIMP3 via a 3’UTR luciferase assay. TIMP3 is a tissue 
inhibitor of metalloproteinases that we found to inhibit MMP activity in HAVECs. 
Additionally, we found that miR-181b increases MMP activity in HAVECs via TIMP3 
silencing. Interestingly, we also showed that OS induces MMP activity in a miR-181b 
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dependent manner, which can be reversed by silencing miR-181b using anti-miR-181b. 
Thus, miR-181b provides a novel therapeutic target to reduce ECM degradation and AV 
sclerosis. 
 We first discovered miR-483 in our HAVEC microRNA array, where it was 
upregulated in LS conditions compared to OS conditions. We further validated miR-483 in 
vitro in HAVECs and in vivo in porcine AVs and found it to be upregulated in LS 
conditions and in the ventricularis side compared to OS conditions and the fibrosa side 
respectively.  We assessed the functional role of miR-483 in HAVECs via monocyte 
adhesion and inflammation marker quantification (inflammation), EndMT marker 
quantification (EndMT), scratch assay (migration), TUNEL assay (apoptosis), and KI67 
staining (proliferation). Our studies showed that mir-483 regulated OS-induced endothelial 
inflammation and EndMT. Treatment with a miR-483 mimic in OS conditions decreased 
inflammation and EndMT; in contrast, silencing of miR-483 in LS conditions by anti-miR-
483 lead to increased inflammation and EndMT in HAVECs. We conducted an in silico 
analysis to determine shear-sensitive targets of miR-483 and identified UBE2C and 
ASH2L. Although both UBE2C and ASH2L are likely to play major roles in CAVD, they 
are potentially involved in two very complex and different pathways (UBE2C on ubiquitin-
dependent pathways and ASH2L on epigenetic regulation through histone modifications). 
Studying both simultaneously would interfere with focused studies; therefore, we decided 
to concentrate on UBE2C for this dissertation and we will conduct an independent study 
on ASH2L to determine its novel functional role in AV endothelial biology and CAVD. 
We further validated that miR-483 regulated mRNA and protein levels of UBE2C via miR-
483 modulation studies in static and shear conditions in HAVECs. 
 Functional studies showed that the protective role of miR-483 is controlled by 
UBE2C. These studies were conducted by co-transfecting HAVECs with anti-miR-483 and 
siUBE2C and assessing endothelial inflammation. Silencing of UBE2C in HAVECs lead 
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to decreased inflammation and EndMT while overexpression of UBE2C lead to increased 
inflammation. UBE2C is an E2 ubiquitin ligase that ubiquitinates proteins, leading to 
degradation via the proteasome pathway.  UBE2C is part of the E3 ligase complex APC/C 
and acts in conjunction with another E2 ligase, UBE2S. UBE2C is an initiating E2 ligase 
responsible for monoubiquitinating substrates while UBE2S recognizes monoubiquitinated 
substrates and extends the ubiquitin chain so that the proteasome recognized the ubiquitin 
chain and degrades the substrate. APC/C and UBE2S are both known to degrade pVHL, a 
major regulator of HIF1α. Here, we showed that UBE2C binds and ubiquitinates pVHL, 
leading to its degradation. Interestingly, our studies showed that for UBE2C to degrade 
pVHL, it requires at least one lysine site in pVHL. Mutation of all the lysine residues in 
pVHL prevents UBE2C-dependent ubiquitination and proteasomal degradation.  Silencing 
of UBE2C reduced HIF1α protein levels in a pVHL-dependent manner. Additionally, we 
studied the function of pVHL and HIF1α in HAVECs and found that pVHL acted as an 
anti-inflammatory and anti-EndMT gene while HIF1α was a pro-inflammatory, pro-
EndMT gene.  
 We conducted therapeutic studies to test whether miR-483 or HIF1α could be used 
to prevent and treat CAVD. To this end, we cultured static porcine AVs ex vivo in 
osteogenic media (DMEM media supplemented with phosphates, dexamethasone, β-
glycerophosphate and TGF-β) and treated with either miR-483 mimic or a HIF1α inhibitor 
(PX478) every three days for two weeks. We observed that both treatments significantly 
decreased calcification, as shown in our Alizarin Red staining and Arsenazo assay. 
Overexpression of miR-483 lead to decreased levels of UBE2C and HIF1α while pVHL 
levels increased. Furthermore, HIF1α levels were significantly upregulated by osteogenic 
media and significantly decreased by treatment with PX478. These studies demonstrate 
that the UBE2C-HIF1α pathway is important for AV calcification and provides preliminary 
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evidence of the therapeutic potential of miR-483 mimic and PX478 as a CAVD medical 
therapy. 
 Last, we are developing an accelerated animal model for CAVD. We used GATA5 
knockout mice, known to develop bicuspid AV (BAV) phenotype, increased AV velocity 
and thickened AV leaflets. We induced hypercholesterolemia in this mouse strain via an 
AAV-PCSK9 injection along with high-fat diet. At eight weeks of age (prior to PCSK9-
injection), ultrasound imaging was conducted on these mice to determine if their AV was 
bicuspid or tricuspid morphologically (if feasible) and by measuring AV velocity. After 
the mice were sorted according to valve phenotype, we injected AAV-PCSK9 and started 
feeding high-fat diet. Monthly ultrasound imaging to assess AV velocity was conducted 
and after four months, the mice were sacrificed. AVs were excised, and we conducted 
immonohistochemical stainings on the valves. We observed that the BAV group had 
developed mild sclerosis and microcalcification nodules while the tricuspid aortic valve 
(TAV) groups had not. Additionally, we showed that subcutaneous injection of 
fluorescently labeled siRNA in mice can be used to deliver oligonucleotide therapies to 
mice AVs.  
 Conclusions 
 We have discovered two novel, shear-sensitive miRNAs in AVs: miR-181b and 
miR-483. We showed that miR-181b, which is upregulated in OS conditions, plays a 
critical role in ECM degradation in AV endothelium by silencing TIMP3; which we found 
to inhibit MMP activity in HAVECs. On the other hand, miR-483 is upregulated in LS 
conditions and targets a novel shear-sensitive gene UBE2C. We identified a novel function 
of UBE2C by targeting and degrading pVHL which in turn leads to the stabilization and 
activation of HIF1α. Through therapeutic studies in porcine AVs using miR-483 mimics 
or HIF1α inhibitors, such as PX478 which is used currently used in clinical trials for cancer 
treatments, we demonstrated their potential as medical therapies for CAVD. Last, we are 
developing an accelerated animal model for CAVD by combining bicuspid AV mice, 
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induced by GATA5  knockdown, with hypercholesterolemia. These mice developed mild 
AV sclerosis, AV stenosis, and microcalcification in the AV leaflets. 
 Future Directions 
 From Aim 1, we identified two additional novel shear-sensitive target genes of 
miR-181b; GATA6 and SIRT1. GATA6 and SIRT1 are known to have a protective role in 
atherosclerosis disease. SIRT1 induces EC relaxation in an angiotensin-induced model of 
atherosclerosis, and it has been shown to inhibit foam cells formation in the vasculature 
[336]. GATA6 inhibits VCAM-1 expression in the endothelium and protects smooth 
muscle cell differentiation [337]. We intend to validate whether miR-181b directly 
regulates GATA6 and SIRT1 via additional miR-181b modulation studies as well as 
3’UTR validation studies. These studies will help us better understand the functional role 
of both miR-181b in valvular endothelial biology and CAVD. Additionally, we are 
interested in studying the role of miR-181b not only in endothelial cells but also in whole 
AV leaflets as well as in valvular interstitial cells. miR-181b plays a role in ECM 
degradation, and we would like to examine its potential in preventing increased ECM 
degradation and sclerosis in porcine AVs treated with osteogenic media as well as in our 
novel GATA5 knockout CAVD model. We are also considering the use of TIMP3 
overexpression in in vitro, ex vivo and in vivo studies to inhibit MMP activity and reduce 
AV calcification. TIMP3 has been shown to play a critical role in atherosclerosis and we 
want to demonstrate whether it is also a critical player in the pathogenesis of CAVD. 
 For Aim 2, we have conducted static ex vivo therapeutic studies which have shown 
the potential of both the miR-483 mimic and HIF1α inhibitor PX478 in significantly 
reducing AV calcification. These studies were done in static cultures of porcine AVs and 
we are interested in validating these results in shear conditions. To this end, we will conduct 
shear stress experiments using the cone-and-plate bioreactors developed by our 
collaborators, Dr. Yoganathan and Dr. Nerem, to study whether miR-483 mimic and 
PX478 can prevent OS-induced porcine AV calcification. These studies will provide 
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further evidence of the therapeutic potential of miR-483 and the HIF1α pathway in treating 
CAVD. Additionally, to better understand the role of these two treatments in the 
pathogenesis of AV calcification, we would like to study the effect of these therapies in 
interstitial cells as well as in our accelerated model of CAVD to determine if treatment 
with miR-483 mimic or PX478 can be used to decrease AV calcification in a more 
clinically relevant model of CAVD.  
 Moreover, we identified pVHL as a shear-sensitive target regulated by UBE2C via 
the ubiquitin-proteasome pathway. UBE2C is an E2 ubiquitin ligase, and its role is to 
ubiquitinate other proteins to induce its degradation via the proteasome. Because there may 
be other proteins that are regulated in a shear-dependent manner by UBE2C we are 
planning on exposing HAVECs to LS or OS conditions followed by immunoprecipitation 
using UBE2C antibodies. The immunoprecipitated proteins will be sent for identification 
via mass spectrometry. In silico studies will be conducted comparing proteins identified 
via mass spectrometry with our HAVEC array data to identify potential shear-sensitive 
targets regulated by UBE2C.  Validation of the identified targets will be conducted to better 
understand the role of UBE2C-dependent ubiquitination in HAVECs.  
 From our in silico studies and in vitro validation, we discovered another target of 
miR-483, ASH2L. ASH2L is a member of the COMPASS complex responsible for 
trimethylating histone 3 lysine (H3K4me3), an epigenetic modification which opens the 
chromatin structure allowing for gene transcription. In order to discover the main target 
genes regulated in OS conditions by ASH2L, we will first expose HAVECs to LS or OS 
conditions followed by chromatin immunoprecipitation (CHIP) studies using ASH2L 
antibodies. The pulled down protein-DNA complex will be sequenced and matched to their 
genomic location via in silico analysis. We will further validate the results from our 
sequencing data by conducting CHIP on sheared HAVECs, followed by qPCR 
amplification of the promoter region of the genes identified in our CHIP studies. These 
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studies will be one of the first to study the role of flow-sensitive epigenetic gene regulation 
in the valvular endothelium. 
 We are currently working in translating the findings from our studies to other 
cardiovascular diseases such as atherosclerosis. To this end, we will try using HIF1α 
inhibitors to treat atherosclerosis. We want to test these therapeutics in two models of 
atherosclerosis commonly used in the Jo lab; partial carotid ligation model as an acute 
model, and long-term high-fat diet chronic study. By repurposing HIF1α inhibitors 
currently in clinical trials for cancer diseases, we expect to accelerate the translation of 
these therapies to the clinic for use in cardiovascular diseases. 
 Furthermore, we want to test our therapeutics findings in our hypercholesterolemic 
GATA5 knockout animal model. We are currently working in testing the role of the HIF1α 
inhibitor, PX478, in this model. We will start PX478 injections in these mice two months 
after hypercholesterolemia induction in order to mimic a more realistic clinical situation 
where the patient will start the treatment not before CAVD has developed but when the 
first signs of the disease can be observed. We will inject biweekly PX478 (or saline control) 
for two more months and then harvest the AV and determine whether PX478 has any effect 
in AV sclerosis and calcification. We are interested in expanding these therapeutic studies 
to study the role of miR-181b and miR-483 in CAVD by injecting either anti-miR-181b or 
miR-483 mimic via subcutaneous injection in a similar experimental design as the PX478 
study. Completion of these studies will be invaluable in accelerating the transition from 
our discoveries to clinical trials. 
 Lastly, even though our subcutaneous injection showed promising results in 
delivering fluorescently labeled siRNAs to the AV, this delivery technique might present 
side-effects due to the non-specific delivery. To address this problem, development of 
targeted delivery to the AV need to be conducted. The fibrosa side is known to have 
increased expression of pro-inflammatory proteins, such as VCAM-1 or ICAM-1, which 
might be used for targeted delivery. Nanoparticles might be functionalized to target these 
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proteins to improve specificity and decrease side-effects. Additional AV markers might be 
needed in order to further increase specificity and will be a challenge for us and other 
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